(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
Jocelyn Arel Jeffrey Letalien Goodwin Procter LLP 620 Eighth Avenue New York, New York 10018 (212) 813-8800 |
Alexandra Low Appleby (Cayman) Ltd. 9th Floor, 60 Nexus Way Camana Bay Grand Cayman, KY1-1104 Cayman Islands (345) 949-4900 |
Joel Rubinstein White & Case LLP 1221 Avenue of the Americ as New York, New York 10020 (212) 819-8200 |
| Large accelerated filer | ☐ |
Accelerated filer | ☐ | |||
☒ |
Smaller reporting company | |||||
| Emerging growth company | ||||||
PER SHARE |
TOTAL |
|||||||
Public offering price |
$ | 10.00 | $ | 75,000,000 | ||||
Underwriting discounts and commissions (1) |
$ | 0.60 | $ | 4,500,000 | ||||
Proceeds, before expenses, to us |
$ | 9.40 | $ | 70,500,000 | ||||
(1) |
Includes $0.20 per Public Share, or $1,500,000 in the aggregate, payable to the underwriters upon the closing of this offering. Also includes $0.40 per share, or $3,000,000 in the aggregate, payable to the underwriters for deferred underwriting commissions to be placed in a trust account located in the United States and released to the underwriters only upon the completion of an initial business combination, as described in this prospectus. See also “Underwriting” for a description of compensation and other items of value payable to the underwriters. |
AS OF AUGUST 21, 2026 | ||||||||||||||||
OFFERING PRICE OF $ SHARE |
25% OF MAXIMUM REDEMPTION |
50% OF MAXIMUM REDEMPTION |
75% OF MAXIMUM REDEMPTION |
MAXIMUM REDEMPTION | ||||||||||||
NTBV |
NTBV |
DIFFERENCE BETWEEN NTBV AND OFFERING PRICE |
NTBV |
DIFFERENCE BETWEEN NTBV AND OFFERING PRICE |
NTBV |
DIFFERENCE BETWEEN NTBV AND OFFERING PRICE |
NTBV |
DIFFERENCE BETWEEN NTBV AND OFFERING PRICE | ||||||||
$ |
$ |
$ |
$ |
$ |
$ |
$ |
$( |
$ | ||||||||
TABLE OF CONTENTS
| PAGE | ||||
| 1 | ||||
| 14 | ||||
| 37 | ||||
| 39 | ||||
| 40 | ||||
| 79 | ||||
| 81 | ||||
| 84 | ||||
| 85 | ||||
| 87 | ||||
| MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
88 | |||
| 93 | ||||
| 123 | ||||
| 132 | ||||
| 135 | ||||
| 137 | ||||
| 152 | ||||
| 160 | ||||
| 168 | ||||
| 169 | ||||
| 170 | ||||
| F-1 | ||||
We have not, and the underwriters have not, authorized anyone to provide you with information that is different from or inconsistent with that contained in this prospectus. We are not, and the underwriters are not, making an offer to sell securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus.
∎ |
“we,” “us,” “company,” “our company” or “FLAC II” are to Frazier Life Sciences Acquisition Corp. II, an exempted company under the laws of the Cayman Islands; |
∎ |
“amended and restated memorandum and articles of incorporation” are to our amended and restated memorandum and articles of incorporation which will be in effect upon effectiveness of the registration statement which this prospectus forms a part; |
∎ |
“Companies Act” are to the Companies Act (As Revised) of the Cayman Islands as the same may be amended from time to time; |
∎ |
“completion window” are to (i) the period ending on the date that is 24 months from the closing of this offering in which we must complete an initial business combination or (ii) such other time period in which we must complete an initial business combination pursuant to an amendment to our amended and restated memorandum and articles of association; |
∎ |
“Continental” or “our transfer agent” are to Continental Stock Transfer & Trust Company, as our transfer agent and the trustee with respect to the trust account; |
∎ |
“forward purchase agreement” are to the forward purchase agreement providing for the sale of forward purchase shares by us to FLSPF in a private placement that will close concurrently with the closing of our initial business combination; |
∎ |
“forward purchase shares” are to the Class A ordinary shares to be issued to FLSPF pursuant to the forward purchase agreement; |
∎ |
“founder shares” are to Class B ordinary shares initially purchased by our sponsor in a private placement prior to this offering and the Class A ordinary shares that will be issued upon the automatic conversion of the Class B ordinary shares at the time of our initial business combination or at any time prior thereto at the option of the holders thereof on a one for one basis, subject to adjustment, as described herein; |
∎ |
“FLS” are to Frazier Life Sciences Management, L.P., an affiliate of our sponsor; |
∎ |
“FLSPF” are to Frazier Life Sciences Public Fund, L.P., a Delaware limited partnership and the purchaser under the forward purchase agreement; |
∎ |
“IPO” are to initial public offering; |
∎ |
“initial shareholders” are to holders of our founder shares prior to this offering; |
∎ |
“Jefferies” are to Jefferies LLC, the representative of the underwriters in this offering; |
∎ |
“M&A” are to mergers and acquisitions; |
∎ |
“management” or our “management team” are to our officers and directors; |
∎ |
“ordinary resolution” are to a resolution of the company passed by a simple majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of the company, or a resolution approved in writing by all of the holders of the issued shares entitled to vote on such matter (or such lower threshold as may be allowed under the Companies Act from time to time and pursuant to our amended and restated memorandum and articles of incorporation); |
∎ |
“ordinary shares” are to our Class A ordinary shares and our Class B ordinary shares; |
∎ |
“private placement shares” are to the Class A ordinary shares to be issued to our sponsor in a private placement simultaneously with the closing of this offering, which private placement shares are |
identical to the Class A ordinary shares sold in this offering, subject to certain limited exceptions as described in this prospectus; |
∎ |
“public shares” are to Class A ordinary shares sold in this offering (whether they are purchased in this |
∎ |
“public shareholders” are to the holders of our public shares, including our initial shareholders and management team, to the extent our initial shareholders and/or members of our management team purchase public shares, provided that each initial shareholder’s and member of our management team’s status as a “public shareholder” will only exist with respect to such public shares; |
∎ |
“share forfeiture” are to the surrender of 281,250 founder shares by our initial shareholders in September 2026 to maintain the target ownership of founder shares by our initial shareholders at 20% of our expected issued and outstanding ordinary shares upon the consummation of this offering; |
∎ |
“special resolution” are to a resolution of the company passed by at least a two-thirds (2/3) majority (or such higher approval threshold as specified in our amended and restated memorandum and articles of association) of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of the company of which notice specifying the intention to propose the resolution as a special resolution has been duly given, or a resolution approved in writing by all of the holders of the issued shares entitled to vote on such matter (or such lower threshold as may be allowed under the Companies Act from time to time and pursuant to our amended and restated memorandum and articles of association); |
∎ |
“sponsor” are to Frazier Life Sciences Holdings II LLC, a Cayman Islands limited liability company; and |
∎ |
Dedicated team and vehicle for public market and crossover investments: follow-on equity offerings, private investments in public equities (“PIPEs”), and open market transactions. |
∎ |
Track record of investing in private companies: |
∎ |
Experienced company founders: in-house professionals who are dedicated to company creation and have historically formed an average of two to three new companies per year. |
∎ |
Deep biopharmaceutical expertise and network: entrepreneurs-in-residence, 1,000-person divisions of large pharmaceutical companies. This group represents strong expertise across the spectrum of drug development in disciplines including medicinal chemistry, pharmacology and translational biology, drug metabolism and pharmacokinetics, toxicology and clinical development. We believe these advisors provide a level of diligence and operational expertise that is critical for both the FLS investment process as well as post-investment value creation. |
∎ |
Leadership continuity: |
∎ |
Targeted product focus |
∎ |
Investing near value inflection points proof-of-concept post-PoC assets, and successful commercial launch post-approval. Consistent with this approach, FLS has historically focused on companies that it believes have the potential to achieve one of these value inflection points within a short time frame following investment. |
∎ |
Backing biopharma performers |
∎ |
Maintaining capital efficiency |
∎ |
Focused on therapeutics for areas of unmet medical need, including in disease areas where FLS has established depth. |
∎ |
Supported by clinical data, or a well-defined path to clinical data, with a value inflection point expected within approximately three years of the business combination. |
∎ |
Led by a management team with a track record of execution and the capability to operate a publicly listed company. |
∎ |
Funded, after giving effect to the business combination, through at least one significant value inflection point. |
ENTITY |
AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES ISSUED OR TO BE ISSUED |
CONSIDERATION PAID OR TO BE PAID | ||
| Frazier Life Sciences Holdings II LLC and other initial shareholders | $ | |||
| Frazier Life Sciences Holdings II LLC | $ | |||
| Frazier Life Sciences Holdings II LLC, an affiliate thereof, or our officers and directors | Repayment in cash or up to $ |
Loans to finance transaction costs in connection with an intended initial business combination | ||
Frazier Life Sciences Holdings II LLC |
Repayment in cash | Up to $ | ||
ENTITY |
AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES ISSUED OR TO BE ISSUED |
CONSIDERATION PAID OR TO BE PAID | ||
| Holders of Class B ordinary shares | Anti-dilution protection upon conversion into Class A ordinary shares at a greater than one-to-one |
Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than one-to-one | ||
| Frazier Life Sciences Holdings II LLC, our officers or directors, or affiliates thereof | Repayment in cash | Any out-of-pocket related to identifying, investigating, negotiating and completing an initial business combination | ||
SUBJECT SECURITIES |
EXPIRATION DATE |
PERSONS SUBJECT TO RESTRICTIONS |
EXCEPTIONS TO TRANSFER RESTRICTIONS | |||
| Founder Shares |
SUBJECT SECURITIES |
EXPIRATION DATE |
PERSONS SUBJECT TO RESTRICTIONS |
EXCEPTIONS TO TRANSFER RESTRICTIONS | |||
| Private Placement Shares | ||||||
Securities offered: |
7,500,000 Class A ordinary shares, at $10.00 per share. |
Proposed Nasdaq symbol |
“FLSC” |
Trading commencement |
The Class A ordinary shares are expected to begin trading on or promptly after the date of this prospectus. |
Number of issued and outstanding before this offering |
1,875,000 |
Number issued and outstanding after this offering and private placement |
9,675,000 (1) |
Forward purchase agreement |
In connection with the consummation of this offering, we plan to enter into a forward purchase agreement with FLSPF, pursuant to which FLSPF will commit that it will purchase from us a minimum of 2,500,000 forward purchase shares, for $10.00 per share, or a minimum aggregate amount of $25,000,000, in a private placement that will close concurrently with the closing of our initial business combination. The proceeds from the sale of these forward purchase shares, together with the amounts available to us from the trust account (after giving effect to any redemptions of public shares) and any other equity or debt financing obtained by us in connection with the business combination, will be used to satisfy the cash requirements of the business combination, including funding the purchase price and paying expenses and retaining specified amounts to be used by the post-business combination company for working capital or other purposes. FLSPF’s commitment under the forward purchase agreement will be subject to approval, prior to our entering into a definitive agreement for our initial business combination, of its investment committee. |
| The forward purchase shares will be identical to the Class A ordinary shares being sold in this offering, except that they will not be transferable, assignable or salable until 30 days after the completion of our initial business combination, except as described herein under |
(1) |
Comprised of 7,500,000 public shares, 1,875,000 founder shares and 300,000 private placement shares. Founder shares are currently classified as Class B ordinary shares, which shares will automatically convert into Class A ordinary shares immediately prior to, concurrently with or immediately following the consummation of our initial business combination or at any time prior thereto at the option of the holder on a one-for-one |
“ Principal Shareholders—Transfers of Founder Shares, Private Placement Shares and Forward Purchase Securities |
Founder shares |
On August 12, 2026, our sponsor paid $25,000 to cover certain of our offering and formation costs in exchange for 2,156,250 founder shares. In August and September 2026, our sponsor transferred an aggregate of 195,190 founder shares to our independent directors and our Chief Financial Officer, Fran Adams. In September 2026, our initial shareholders surrendered an aggregate of 281,250 founder shares to us for no consideration to maintain the ownership of founder shares by our initial shareholders, on an as-converted basis, at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares). Following the share forfeiture, our initial shareholders currently hold 1,875,000 founder shares, or approximately $0.013 per share based on the initial $25,000 paid by our sponsor. |
| Prior to the initial investment in the company of $25,000 by the sponsor, the company had no assets, tangible or intangible. The per share price of the founder shares was determined by dividing the amount of cash contributed to the company by the number of founder shares issued. The number of founder shares outstanding was determined based on the expectation that the total size of this offering would be a maximum of 7,500,000, and therefore that such founder shares would represent 20% of the outstanding shares after this offering (excluding the private placement shares). If we increase or decrease the size of the offering pursuant to Rule 462(b) under the Securities Act, we will effect a share capitalization or a share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our Class B ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders, on an as-converted basis, at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares). Any conversion of Class B ordinary shares described herein will take effect as a redemption of Class B ordinary shares and an issuance of Class A ordinary shares as a matter of Cayman Islands law. |
| The founder shares are identical to the Class A ordinary shares being sold in this offering, except that: |
∎ |
prior to the closing of our initial business combination and while any Class B ordinary shares are issued and outstanding, only holders of Class B ordinary shares will be entitled to vote on certain matters as described below adjacent to the caption “Voting”; |
∎ |
the founder shares are subject to certain transfer restrictions, as described in more detail below; |
∎ |
the founder shares are entitled to registration rights; |
∎ |
our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to |
(i) waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may acquire during or after this offering in connection with the completion of our initial business combination; (ii) waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may acquire during or after this offering in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated an initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity; (iii) waive their rights to liquidating distributions from the trust account with respect to their founder shares and private placement shares if we fail to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions from the trust account with respect to any public shares they hold if we fail to complete our initial business combination within the prescribed time frame and to liquidating distributions from assets outside the trust account; and (iv) vote any founder shares and private placement shares held by them and any public shares purchased during or after this offering (including in open market and privately negotiated transactions) in favor of our initial business combination (except with respect to any such public shares which may not be voted in favor of approving the business combination transaction in accordance with the requirements of Rule 14e-5 under the Exchange Act and any SEC interpretations or guidance relating thereto). If we submit our initial business combination to our public shareholders for a vote, we will complete our initial business combination only if we receive an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of our ordinary shares which are represented in person or, where proxies are allowed, by proxy and are voted at a general meeting of the company, voting together as a single class. As a result, in addition to our initial shareholders’ founder shares and the private placement shares, we would need 2,662,501, or 35.5%, of the 7,500,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved by way of ordinary resolution (assuming all outstanding shares are voted and the parties to the letter agreement do not acquire any public shares). Assuming that only one-third of our issued and outstanding ordinary shares, representing a quorum under our amended and restated memorandum and articles of association, are voted, our founder shares and private placement shares voted in favor of an initial business combination will be |
sufficient in order to have an initial business combination approved by way of ordinary resolution; and |
∎ |
the founder shares are automatically convertible into our Class A ordinary shares immediately prior to, concurrently with or immediately following the consummation of our initial business combination or at any time prior thereto at the option of the holder on a one-for-one |
Private placement shares: |
Our sponsor has agreed to purchase an aggregate of 300,000 private placement shares, at a price of $10.00 per share, for an aggregate purchase price of $3,000,000, in a private placement that will close simultaneously with the closing of this offering. A portion of the purchase price of the private placement shares will be added to the proceeds from this offering to be held in the trust account such that at the time of closing of this offering $75,000,000 will be held in the trust account. The private placement shares will be identical to the shares sold in this offering except that (i) the private placement shares may not, subject to certain limited exceptions, be transferred, assigned or sold by the holders until 30 days after the completion of our initial business combination and (ii) the private placement shares will be entitled to registration rights. |
| The private placement shares purchased by the underwriters or their affiliates are deemed underwriters’ compensation by FINRA pursuant to Rule 5110 of the FINRA Manual. |
| Our sponsor and the underwriters have agreed to (i) waive their redemption rights with respect to their private placement shares in connection with the completion of our initial business combination, (ii) waive their redemption rights with respect to their private placement shares in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated an initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity, (iii) waive their rights to liquidating distributions from the trust account with respect to their private placement shares if we fail to complete our initial business combination within the completion window, and (iv) vote any private placement shares held by them in favor of our initial business combination. |
Transfer restrictions on founder shares and private placement shares: |
Our initial shareholders have agreed not to transfer, assign or sell any of their founder shares and any Class A ordinary shares issuable upon conversion thereof until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any 30-trading day period commencing at least 180 days after |
the completion of our initial business combination, and our sponsor has agreed not to transfer, assign or sell any of its private placement shares until 30 days after the completion of our initial business combination; except, in each case, to certain permitted transferees and under certain circumstances as described herein under “Principal Shareholders—Transfers of Founder Shares, Private Placement Shares and Forward Purchase Securities”. Any permitted transferees will be subject to the same restrictions and other agreements of our initial shareholders with respect to any founder shares or private placement shares. We refer to such transfer restrictions throughout this prospectus as the lock-up. |
Founder shares conversion and anti-dilution rights: |
The founder shares will automatically convert into Class A ordinary shares immediately prior to, concurrently with or immediately following the consummation of our initial business combination or at any time prior thereto at the option of the holder on a one-for-one sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional Class A ordinary shares or equity-linked securities are issued or deemed issued in connection with our initial business combination, the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, 20% of the total number of Class A ordinary shares outstanding after such conversion (excluding the private placement shares and forward purchase shares, and after giving effect to any redemptions of Class A ordinary shares by public shareholders), including the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the company in connection with or in relation to the consummation of the initial business combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, or to be issued, to any seller in the initial business combination and any private placement shares issued to our sponsor, officers or directors upon conversion of working capital loans; provided that such conversion of founder shares will never occur on a less than one-for-one |
Voting: |
Prior to the closing of our initial business combination and while any Class B ordinary shares are issued and outstanding, only holders of Class B ordinary shares will have the right to vote on the appointment and removal of directors or continuing the company in a jurisdiction outside of the Cayman Islands (including any special resolution required to amend the constitutional documents of the Company or to adopt new constitutional documents of the Company, in each case, as a result of the Company approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands). With respect to any other matter submitted to a vote of our shareholders prior to or in connection with the completion of our initial business combination, including any vote in connection with our initial |
business combination, except as required by law, holders of our founder shares and holders of our public shares will vote together as a single class, with each share entitling the holder to one vote. These provisions of our amended and restated memorandum and articles of association may only be amended by a special resolution passed by a majority of at least 90% (or, where such amendment is proposed in respect of the consummation of our initial business combination, two thirds) of our ordinary shares which are represented in person or by proxy and are voted at our general meeting. |
Proceeds to be held in trust account: |
Nasdaq rules provide that at least 90% of the gross proceeds from this offering and the sale of the private placement shares be deposited in a trust account. Of the net proceeds we will receive from this offering and the sale of the private placement shares described in this prospectus, $75,000,000 ($10.00 per share) will be deposited into a segregated trust account located in the United States with Continental acting as trustee, after deducting $1,500,000 in underwriting discounts and commissions payable upon the closing of this offering and an aggregate of $750,000 to pay fees and expenses in connection with the closing of this offering and $1,500,000 for working capital following the closing of this offering. The proceeds to be placed in the trust account include $3,000,000 in deferred underwriting commissions. |
| Except with respect to interest earned on the funds held in the trust account that may be released to us to pay our taxes, if any, the proceeds from this offering and the sale of the private placement shares will not be released from the trust account until the earliest of (i) in connection with the completion of our initial business combination, (ii) the redemption of our public shares if we are unable to complete our initial business combination within the completion window, subject to applicable law or (iii) the redemption of our public shares properly submitted in connection with a shareholder vote to amend our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated an initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity. The proceeds deposited in the trust account could become subject to the claims of our creditors, if any, which could have priority over the claims of our public shareholders. |
Ability to extend time to complete business combination: |
We have until the date that is 24 months from the closing of this offering, or such other time period in which we must complete an initial business combination pursuant to an amendment to our amended and restated memorandum and articles of association, to consummate our initial business combination. If we anticipate that we may be unable to consummate our initial business combination |
within the completion window, we may seek shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial business combination. If we seek shareholder approval for an extension, holders of our Class A ordinary shares will be offered an opportunity to redeem their shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein, regardless of whether they abstain, vote in favor of or vote against such extension. |
| Our initial shareholders will lose their entire investment in us if our initial business combination is not completed within the completion window unless we extend the amount of time we have to consummate an initial business combination by obtaining shareholder approval to amend our amended and restated memorandum and articles of association. While we do not currently intend to seek such an extension, we may elect to do so in the future. There is no limit on the number of extensions that we may seek; however, we do not expect to extend the time period to consummate our initial business combination beyond 36 months from the closing of this offering, in compliance with Nasdaq Rule IM 5101-2. If we do not or are unable to extend the time period to consummate our initial business combination, our sponsor’s investment in our founder shares and our private placement shares may be worthless. |
| If we are unable to complete our initial business combination within the completion window and do not hold a shareholder vote to amend our amended and restated memorandum and articles of association to extend the amount of time we will have to consummate an initial business combination, we will redeem 100% of the public shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law and certain conditions as further described herein. |
Anticipated expenses and funding sources |
Unless and until we complete our initial business combination, no proceeds held in the trust account will be available for our use, except the withdrawal of interest to pay our taxes (other than excise or similar taxes) and/or to redeem our public shares in connection with an amendment to our amended and restated memorandum and articles of association, as described above. The proceeds held in the trust account will initially be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money |
market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination and may at any time be held as cash or cash items, including in demand deposit accounts at a bank. We will disclose in each quarterly and annual report filed with the SEC prior to our initial business combination whether the proceeds deposited in the trust account are invested in U.S. government treasury obligations or money market funds or a combination thereof or as cash or cash items, including in demand deposit accounts. |
| Unless and until we complete our initial business combination, we may pay our expenses only from: |
∎ |
the net proceeds of this offering and the sale of the private placement shares not held in the trust account, which initially will be approximately $1,500,000 in working capital after the payment of approximately $750,000 in expenses relating to this offering; and |
∎ |
any loans or additional investments from our sponsor, members of our management team or their affiliates or other third parties, although they are under no obligation to advance funds or invest in us; provided that any such loans will not have any claim on the proceeds held in the trust account unless such proceeds are released to us in connection with the completion of our initial business combination. Up to $3,000,000 of such loans may be convertible into private placement shares, at a price of $10.00 per share, at the option of the lender. |
Conditions to completing our initial business combination: |
Nasdaq rules require that we must complete one or more business combinations having an aggregate fair market value of at least 80% of the value of the assets held in the trust account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the trust account) at the time of the agreement to enter into the initial business combination. Our board of directors will make the determination as to the fair market value of our initial business combination. If our board of directors is not able to independently determine the fair market value of our initial business combination (including with the assistance of financial advisors), we will obtain an opinion from an independent investment banking firm or an independent valuation or accounting firm. While we consider it likely that our board of directors will be able to make an independent determination of the fair market value of our initial business combination, it may be unable to do so if it is less familiar or experienced with the business of a particular target or if there is a significant amount of uncertainty as to the value of the target’s assets or prospects. Additionally, pursuant to Nasdaq rules, any initial business combination must be approved by a majority of our independent directors. We will complete our initial business combination only if the post-transaction company in which our public shareholders own shares will own or acquire 50% or more of |
the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act. Even if the post-transaction company owns or acquires 50% or more of the voting securities of the target, our shareholders prior to our initial business combination may collectively own a minority interest in the post business combination company, depending on valuations ascribed to the target and us in the business combination transaction. For example, we could pursue a transaction in which we issue a substantial number of new shares in exchange for all of the outstanding capital stock, shares or other equity interests of a target. In this case, we would acquire a 100% controlling interest in the target. However, as a result of the issuance of a substantial number of new shares, our shareholders immediately prior to our initial business combination could own less than a majority of our issued and outstanding shares subsequent to our initial business combination. If less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the post-transaction company, the portion of such business or businesses that is owned or acquired is what will be taken into account for purposes of the 80% of net assets test described above, provided that in the event that the business combination involves more than one target business, the aggregate value of all of the target businesses will be taken into account for purposes of the 80% fair market value test and we will treat the transactions together as our initial business combination for purposes of seeking shareholder approval or conducting a tender offer, as applicable. |
Permitted purchases of public shares by our affiliates: |
If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, initial shareholders directors, officers, advisors and their affiliates may purchase public shares in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. There is no limit on the number of shares our initial shareholders, directors, officers, advisors or their affiliates may purchase in such transactions, subject to compliance with applicable law and Nasdaq rules. However, they have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions. None of the funds held in the trust account will be used to purchase public shares in such transactions. If they engage in such transactions, they will not make any such purchases when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Securities Exchange Act of 1934, as amended, or the Exchange Act. We do not currently anticipate that such purchases, if any, would constitute a tender offer subject to the tender offer rules under the Exchange Act or a going-private transaction subject to the going-private rules under the Exchange |
Act; however, if the purchasers determine at the time of any such purchases that the purchases are subject to such rules, the purchasers will comply with such rules. Any such purchases will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers are subject to such reporting requirements See “ Proposed Business—Effecting Our Initial Business Combination—Permitted Purchases of Our Securities 10b-5 of the Exchange Act. |
| Additionally, in the event our sponsor, initial shareholders, directors, officers, advisors or their affiliates were to purchase shares from public shareholders, such purchases would be structured in compliance with the requirements of Rule 14e-5 under the Exchange Act including, in pertinent part, through adherence to the following: |
∎ |
our registration statement/proxy statement filed for our business combination transaction would disclose the possibility that our sponsor, initial shareholders, directors, officers, advisors or their affiliates may purchase shares from public shareholders outside the redemption process, along with the purpose of such purchase; |
∎ |
if our sponsor, initial shareholders, directors, officers, advisors or their affiliates were to purchase shares from public shareholders, they would do so at a price no higher than the price offered through our redemption process; |
∎ |
our registration statement/proxy statement filed for our business combination transaction would include a representation that any of our securities purchased by our sponsor, initial shareholders, directors, officers, advisors or their affiliates would not be voted in favor of approving the business combination transaction; |
∎ |
our sponsor, initial shareholders, directors, officers, advisors or their affiliates would not possess any redemption rights with respect to our securities or, if they do acquire and possess redemption rights, they would waive such rights; and |
∎ |
we would disclose in a Form 8-K, before our general meeting to approve the business combination transaction, the following material items: (i) the amount of our securities purchased outside of the redemption offer by our sponsor, initial shareholders, directors, officers, advisors or their affiliates, along with the purchase price; (ii) the purpose of the purchases by our sponsor, initial shareholders, directors, officers, advisors or their affiliates; (iii) the impact, if any, of the purchases by our sponsor, initial shareholders, directors, officers, advisors or their affiliates on the likelihood that the business combination transaction will be approved; (iv) the identities of our security holders who sold to our sponsor, initial shareholders, directors, officers, advisors or their affiliates (if not purchased on the open |
market) or the nature of our security holders (e.g., 5% security holders) who sold to our sponsor, initial shareholders, directors, officers, advisors or their affiliates; and (v) the number of our securities for which we have received redemption requests pursuant to our redemption offer. |
| Please see “ Proposed Business—Permitted Purchases of Our Securities |
| The purpose of any such purchases of shares could be to increase the likelihood of obtaining shareholder approval of the initial business combination or to satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash at the closing of our initial business combination, where it appears that such requirement would otherwise not be met. Any such purchases of our securities may result in the completion of our initial business combination that may not otherwise have been possible. In addition, if such purchases are made, the public “float” of our Class A ordinary shares may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities on a national securities exchange. |
Redemption rights for public shareholders in connection with the completion of our initial business combination: |
We will provide our public shareholders with the opportunity to redeem all or a portion of their public shares in connection with the completion of our initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein. The amount in the trust account is initially anticipated to be $10.00 per public share. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions we will pay to the underwriters. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may acquire during or after this offering in connection with the completion of our initial business combination. |
Manner of conducting redemptions: |
We will provide our public shareholders with the opportunity to redeem all or a portion of their public shares in connection with the completion of our initial business combination either (i) in |
connection with a general meeting called to approve the initial business combination or (ii) without a shareholder vote by means of a tender offer. The decision as to whether we will seek shareholder approval of a proposed initial business combination or conduct a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require us to seek shareholder approval under applicable law or stock exchange listing requirements. Asset acquisitions and share purchases would not typically require shareholder approval while direct mergers with our company where we do not survive and any transactions where we issue more than 20% of our issued and outstanding Class A ordinary shares or seek to amend our amended and restated memorandum and articles of association would require shareholder approval. So long as we obtain and maintain a listing for our securities on Nasdaq, we will be required to comply with Nasdaq’s shareholder approval rules. |
| The requirement that we provide our public shareholders with the opportunity to redeem their public shares by one of the two methods listed above will be contained in provisions of our amended and restated memorandum and articles of association and will apply whether or not we maintain our registration under the Exchange Act or our listing on Nasdaq. Such provisions may be amended if approved by a special resolution passed by the affirmative vote of at least two-thirds of our ordinary shares which are represented in person or by proxy and are voted at a general meeting of the company. |
| If we provide our public shareholders with the opportunity to redeem their public shares in connection with a general meeting, we will: |
∎ |
conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules, and |
∎ |
file proxy materials with the SEC. |
If we seek shareholder approval, we will complete our initial business combination only if we receive an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a simple majority of the votes cast by the holders of our ordinary shares which are represented in person or, where proxies are allowed, by proxy and entitled to vote on such matter at a general meeting of the company. A quorum for such meeting will be present if the holders of one-third of issued and outstanding shares entitled to vote at the meeting are represented in person or by proxy. Our initial shareholders will count toward this quorum and, pursuant to the letter agreement, our sponsor, officers and directors have agreed to vote their founder shares, private placement shares and any public shares purchased during or after this offering (including in open market and privately-negotiated transactions) in favor of our initial business combination (except with respect to any such public shares which may not be |
voted in favor of approving the business combination transaction in accordance with the requirements of Rule 14e-5 under the Exchange Act and any SEC interpretations or guidance relating thereto). For purposes of seeking approval of an ordinary resolution, non-votes will have no effect on the approval of our initial business combination once a quorum is obtained. As a result, in addition to our initial shareholders’ founder shares and the private placement shares, we would need 2,662,501, or 35.5%, of the 7,500,000 public shares sold in this offering to be voted in favor of an initial business combination in order to have our initial business combination approved by way of ordinary resolution (assuming all outstanding shares are voted and the parties to the letter agreement do not acquire any public shares). Assuming that only one-third of our issued and outstanding ordinary shares, representing a quorum under our amended and restated memorandum and articles of association, are voted, our founder shares and private placement shares voted in favor of an initial business combination will be sufficient in order to have an initial business combination approved by way of ordinary resolution. However, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution passed by the affirmative vote of a majority of at least two-thirds of the votes cast by the holders of our ordinary shares which are represented in person or, where proxies are allowed, by proxy and entitled to vote on such matter at a general meeting of the company of which notice specifying the intention to propose the resolution as a special resolution has been duly given. These quorum and voting thresholds, and the voting agreements of our initial shareholders, may make it more likely that we will consummate our initial business combination. Each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction or whether they do not vote or abstain from voting on the proposed transaction, or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction. If we seek shareholder approval for an extension, holders of our public shares will be offered an opportunity to redeem their shares upon approval of such extension, regardless of whether they abstain, vote in favor of or vote against such extension. |
| If a shareholder vote is not required and we do not decide to hold a shareholder vote for business or other legal reasons, we will: |
∎ |
conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and |
∎ |
file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about our initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
| In the event we conduct redemptions pursuant to the tender offer rules, our offer to redeem will remain open for at least 20 business days, in accordance with Rule 14e-1(a) under the Exchange Act, and we will not be permitted to complete our initial business combination until the expiration of the tender offer period. In addition, the tender offer will be conditioned on public shareholders not tendering more than the number of shares we are permitted to redeem. If public shareholders tender more shares than we have offered to purchase, we will withdraw the tender offer and not complete such initial business combination. |
| Upon the public announcement of our initial business combination, if we elect to conduct redemptions pursuant to the tender offer rules, we or our sponsor will terminate any plan established in accordance with Rule 10b5-1 to purchase our Class A ordinary shares in the open market, in order to comply with Rule 14e-5 under the Exchange Act. |
| We intend to require our public shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street name,” to, at the holder’s option, either deliver their share certificates to our transfer agent or deliver their shares to our transfer agent electronically using the Depository Trust Company’s DWAC (Deposit/Withdrawal At Custodian) system, prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy materials, this date may be up to two business days prior to the scheduled vote on the proposal to approve the initial business combination. In addition, if we conduct redemptions in connection with a shareholder vote, we intend to require a public shareholder seeking redemption of its public shares to also submit a written request for redemption to our transfer agent two business days prior to the scheduled vote in which the name of the beneficial owner of such shares is included. |
| The proxy materials or tender offer documents, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will indicate whether we are requiring public shareholders to satisfy such delivery requirements. We believe that this will allow our transfer agent to efficiently process any redemptions without the need for further communication or action from the redeeming public shareholders, which could delay redemptions and result in additional administrative cost. If the proposed initial business combination is not approved and we continue to search for a target company, we will promptly return any certificates or shares delivered by public shareholders who elected to redeem their shares. |
Our proposed initial business combination may impose a minimum cash requirement for (i) cash consideration to be paid to the target or its owners, (ii) cash for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions. In the event the aggregate cash consideration we would be required to pay for all Class A ordinary shares that are validly submitted for |
redemption plus any amount required to satisfy cash conditions pursuant to the terms of the proposed initial business combination exceed the aggregate amount of cash available to us, we will not complete the initial business combination or redeem any shares, and all Class A ordinary shares submitted for redemption will be returned to the holders thereof. We may, however, raise funds through the issuance of equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop arrangements we may enter into following consummation of this offering, in order to, among other reasons, satisfy such net tangible assets or minimum cash requirements. |
Limitation on redemption rights of shareholders holding 15% or more of the shares sold in this offering if we hold shareholder vote: |
Notwithstanding the foregoing redemption rights, if we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our amended and restated memorandum and articles of association provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares sold in this offering without our prior consent. We believe the restriction described above will discourage shareholders from accumulating large blocks of shares, and subsequent attempts by such holders to use their ability to redeem their shares as a means to force us or our management to purchase their shares at a significant premium to the then—current market price or on other undesirable terms. Absent this provision, a public shareholder holding more than an aggregate of 15% of the shares sold in this offering could threaten to exercise its redemption rights against a business combination if such holder’s shares are not purchased by us, our sponsor or our management at a premium to the then current market price or on other undesirable terms. By limiting our shareholders’ ability to redeem to no more than 15% of the shares sold in this offering, we believe we will limit the ability of a small group of shareholders to unreasonably attempt to block our ability to complete our initial business combination, particularly in connection with a business combination with a target that requires as a closing condition that we have a minimum net worth or a certain amount of cash. However, we would not be restricting our shareholders’ ability to vote all of their shares (including all shares held by those shareholders that hold more than 15% of the shares sold in this offering) for or against our initial business combination. |
Release of funds in trust account on closing of our initial business combination: |
In connection with the completion of our initial business combination, the funds held in the trust account will be used to pay |
amounts due to any public shareholders who exercise their redemption rights as described above under “ Redemption rights for public shareholders in connection with the completion of our initial business combination |
Redemption of public shares and distribution and liquidation if no initial business combination: |
Our amended and restated memorandum and articles of association provide that we will have only the completion window to complete our initial business combination. If we are unable to complete our initial business combination within the completion window, we will as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will constitute full and complete payment for the public shares and completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation or other distributions, if any), subject, in each case to our obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. |
Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have waived their rights to liquidating distributions from the trust account with respect to any founder shares and private placement shares held by them if we fail to complete our initial business combination within the completion window, although they will be entitled to liquidating distributions from assets outside the trust account. However, if they acquire public shares in or after this offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our initial business combination within the completion window. The underwriters have agreed to waive their rights to their deferred underwriting commission held in the trust account in the event we do not complete our initial business |
combination within the completion window and, in such event, such amounts will be included with the funds held in the trust account that will be available to fund the redemption of our public shares. |
| Our sponsor, officers and directors have agreed, pursuant to a letter agreement, that they will not propose any amendment to our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity, unless we provide our public shareholders with the opportunity to redeem their Class A ordinary shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described above under “Limitations on redemptions |
Redemption rights for public shareholders upon amendment of our amended and restated memorandum and articles of association: |
If we seek to amend our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity, we will provide our public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the approval of such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein. |
Payments to insiders: |
Prior to or in connection with our initial business combination, we expect to make certain payments and reimbursements to our sponsor, officers or directors, or our or their affiliates, including but |
not limited to the following, which, if made prior to our initial business combination will be made from funds held outside the trust account: |
∎ |
Repayment of up to $300,000 in loans made to us by our sponsor to cover offering-related and organizational expenses; |
∎ |
∎ |
Payments to any business development consultant or personnel we may engage or employ in connection with our search for and/ or consummation of our initial business combination; and |
| Repayment of loans which may be made by our sponsor or an affiliate of our sponsor or certain of our officers and directors to finance transaction costs in connection with an intended initial business combination. Up to $3,000,000 of such loans may be convertible into private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender. Such shares would be identical to the private placement shares. Except for the foregoing, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. |
Audit committee: |
We will establish and maintain an audit committee, which will be comprised entirely of independent directors as and when required by the rules of Nasdaq and Rule 10A of the Exchange Act. Among its responsibilities, the audit committee will review on a quarterly basis all payments that were made to our sponsor, officers or directors, and our or their affiliates and monitor compliance with the other terms relating to this offering. If any noncompliance is identified, then the audit committee will be charged with the responsibility to promptly take all action necessary to rectify such noncompliance or otherwise to cause compliance with the terms of this offering. For more information, see the section entitled “ Management—Committees of the Board of Directors—Audit Committee |
Conflicts of Interest: |
opportunities to us or to any other special purpose acquisition company with which they may become involved. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination target. However, because the other entities to which our officers and directors currently owe fiduciary duties or contractual obligations are not themselves in the business of engaging in business combinations, and because we expect that our company will generally have priority over any other special purpose acquisition companies subsequently incorporated by our sponsor, officers or directors with respect to acquisition opportunities until we complete our initial business combination or enter into a contractual agreement that would restrict our ability to engage in material discussions regarding a potential initial business combination, we do not believe that any such potential conflicts would materially affect our ability to complete our initial business combination. |
| Our executive officers and our directors may have interests that differ from you in connection with the business combination, including the fact that they may lose their entire investment in us if our initial business combination is not completed, except to the extent they receive liquidating distributions from assets outside the trust account, and accordingly, may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction. Additionally, the personal and financial interests of our directors and executive officers may influence their motivation in timely identifying and pursuing an initial business combination or completing our initial business combination. For example, our directors and executive officers may prioritize a prospective initial business combination with a shorter timeline to completion over another acquisition target which may be more difficult or time-intensive to consummate. Consequently, our directors’ and executive officers’ discretion in identifying and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and in our shareholders’ best interest, which could negatively impact the timing for a business combination. |
| In addition to the above, our officers and directors are not required to commit any specified amount of time to our affairs, and, accordingly, may have conflicts of interest in allocating management time among various business activities, including selecting a business combination target and monitoring the related due diligence. |
Additionally, our sponsor and executive officers and directors have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares held by them in connection with the consummation of our initial business combination. Further, our sponsor and executive officers and directors have agreed to waive their redemption rights with respect to |
any founder shares held by them if we are unable to complete our initial business combination within the completion window. With certain limited exceptions, the founder shares will not be transferable, assignable or salable by our sponsor or its permitted transferees until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any 30-trading day period commencing at least 180 days after the completion of our initial business combination. |
| Affiliates of FLS and members of our board of directors will directly or indirectly own our securities following this offering, and accordingly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. Our sponsor paid a nominal aggregate purchase price of $25,000 for the founder shares, or approximately $0.013 per share. Accordingly, our management team, which owns interests in our sponsor, may be more willing to pursue a business combination with a riskier or less-established target business than would be the case if our sponsor had paid the same per share price for the founder shares as our public shareholders paid for their public shares. |
| In the event our sponsor or members of our management team provide loans to us to finance transaction costs and/or incur expenses on our behalf in connection with an initial business combination, such persons may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction as such loans may not be repaid and/or such expenses may not be reimbursed unless we consummate such business combination. |
We are not prohibited from pursuing an initial business combination or subsequent transaction with a company that is affiliated with FLS, our sponsor, founders, officers or directors; accordingly, such affiliated person(s) may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction as such affiliated person(s) would have interests different from our public shareholders and would likely not receive any financial benefit unless we consummated such business combination. In the event we seek to complete an initial business combination with a target that is affiliated (as defined in our amended and restated memorandum and articles of association) with our sponsor, executive officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent investment banking firm or an independent valuation or accounting firm stating that the |
consideration to be paid by us in such an initial business combination is fair to our company from a financial point of view. We are not required to obtain such an opinion in any other context. |
Indemnity by the sponsor in the event of liquidation without a business combination: |
Our sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered or products sold to us, or a prospective target business with which we have entered into a written letter of intent, confidentiality or other similar agreement or business combination agreement (except for the Company’s independent auditors), reduce the amount of funds in the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under our indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, we have not asked our sponsor to reserve for such indemnification obligations, nor have we independently verified whether our sponsor has sufficient funds to satisfy its indemnity obligations and we believe that our sponsor’s only assets are securities of our company. Therefore, we cannot assure you that our sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the trust account, the funds available for our initial business combination and redemptions could be reduced to less than $10.00 per public share. |
Additional Financings: |
We intend to effectuate our initial business combination using cash from the proceeds of this offering, the sale of the private placement shares and forward purchase shares, our equity, debt or a combination of these as the consideration to be paid in our initial business combination. Generally, the issuance of additional shares in a business combination: |
∎ |
may significantly dilute the equity interest of investors in this offering, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one |
∎ |
may subordinate the rights of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded our Class A ordinary shares; |
∎ |
could cause a change in control if a substantial number of our Class A ordinary shares are issued; |
∎ |
may have the effect of delaying or preventing a change of control by diluting the share ownership or voting rights of a person seeking to obtain control; and |
∎ |
may adversely affect prevailing market prices for our Class A ordinary shares. |
We may also issue shares in private placement transactions (so-called PIPE transactions) in connection with our initial business combination, for instance in order to provide sufficient liquidity and capital to the post-business combination entity. As of the date of this prospectus, we have no commitments to issue any shares in connection with such a transaction. The price of the shares we may issue in such a transaction may be less, and potentially significantly less, than $10.00 per share or the market price for our shares at such time. Any such issuances of equity securities at a price that is less than $10.00 or the prevailing market price of our shares at that time could be structured to ensure a return on investment to the investors and could dilute the interests of our existing shareholders in a manner that would not ordinarily occur in a traditional initial public offering and could result in both a reduction in the trading price of our shares to the price at which we issue such equity securities and fluctuations in the net tangible book value per share of the combined company’s securities following the completion of our initial business combination. We may also provide price protection or other incentives, or issue convertible securities such as preferred equity or convertible debt, and the exercise or conversion price of those securities may be fixed or adjustable, and may be less, and potentially significantly less, than $10.00 per share or the market price for our shares at such time. Such issuances could also result in additional transaction costs related to our initial business combination compared to a traditional initial public offering, including the placement fees associated with the engagement of a placement agent in connection with PIPE transactions. The issuance of additional ordinary or preference shares may significantly dilute the equity interest of investors in this offering and are likely to increase as the enterprise value of a prospective target company increases. We intend to focus on companies that have an aggregate enterprise value which is greater than we could acquire with the net proceeds of this offering and the sale of the private placement shares and the forward purchase shares. Further, such dilution would even further increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one |
earn-outs or other restrictions, and (iii) enter into any other arrangements with respect to any such securities. |
| Although we have no commitments as of the date of this prospectus to issue any notes or other debt, or to otherwise incur debt following this offering, we may choose to incur substantial debt to complete our initial business combination. As such, no issuance of debt will affect the per share amount available for redemption from the trust account. |
∎ |
We are a blank check company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective. |
∎ |
Our public shareholders may not be afforded an opportunity to vote on our proposed initial business combination, and even if we hold a vote, holders of our founder shares will participate in such vote, which means we may complete our initial business combination even though a majority of our public shareholders do not support such a business combination. |
∎ |
Your only opportunity to effect your investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash. |
∎ |
∎ |
The ability of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target. |
∎ |
The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares and the amount of deferred underwriting compensation may not allow us to complete the most desirable business combination or optimize our capital structure, and may substantially dilute your investment in us. |
∎ |
The requirement that we complete our initial business combination within the completion window may give potential target businesses leverage over us in negotiating a business combination and may limit the time we have in which to conduct due diligence on potential business combination targets, in particular as we approach our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce value for our shareholders. |
∎ |
If we seek shareholder approval of our initial business combination, our sponsor, initial shareholders, directors, officers, advisors and their affiliates may elect to purchase public shares from public shareholders, which may influence a vote on a proposed business combination and reduce the public “float” of our Class A ordinary shares. |
∎ |
If a shareholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for submitting or tendering its shares, such shares may not be redeemed. |
∎ |
You will not have any rights or interests in funds from the trust account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your public shares, potentially at a loss. |
∎ |
Nasdaq may delist our Class A ordinary shares from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions. |
∎ |
You will not be entitled to protections normally afforded to investors of many other blank check companies. |
∎ |
Because of our limited resources and the significant competition for business combination opportunities, it may be more difficult for us to complete our initial business combination and to negotiate attractive acquisition terms. If we have not completed our initial business combination |
within the completion window, our public shareholders may receive only their pro rata portion of the funds in the trust account that are available for distribution to public shareholders. |
∎ |
If the net proceeds of this offering and the sale of the private placement shares not being held in the trust account are insufficient to allow us to operate for at least the duration of the completion window, it could limit the amount available to fund our search for a target business or businesses and complete our initial business combination, and we will depend on loans from our sponsor, its affiliates or our management team to fund our search and to complete our initial business combination. |
∎ |
Past performance by our management team or their respective affiliates may not be indicative of future performance of an investment in us. |
∎ |
The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination. |
∎ |
Unlike some other similarly structured special purpose acquisition companies, our initial shareholders will receive additional Class A ordinary shares if we issue certain shares to consummate an initial business combination. |
∎ |
We may be a passive foreign investment company, or “PFIC,” which could result in adverse United States federal income tax consequences to U.S. investors. |
∎ |
We may transfer by way of continuation to another jurisdiction, which may result in taxes imposed on shareholders. |
∎ |
Our initial business combination and our structure thereafter may not be tax-efficient to our shareholders. As a result of our business combination, our tax obligations may be more complex, burdensome and uncertain. |
∎ |
Because we are incorporated under the laws of the Cayman Islands, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. Federal courts may be limited. |
∎ |
In recent years, the number of special purpose acquisition companies that have been incorporated has increased substantially, potentially resulting in more competition for attractive targets. This could increase the cost of our initial business combination and could even result in our inability to find a target or to consummate an initial business combination. |
∎ |
The other risks and uncertainties discussed in “Risk Factors” and elsewhere in this prospectus. |
AUGUST 21, 2026 |
||||||||
ACTUAL |
AS ADJUSTED |
|||||||
Balance Sheet Data: |
||||||||
Working capital (deficiency) |
$ | (45,651 | ) | $ | 1,518,477 | |||
Total assets |
$ | 101,105 | $ | 76,518,477 | ||||
Total liabilities |
$ | 82,628 | $ | 3,000,000 | ||||
Value of Class A ordinary shares subject to possible redemption |
$ | — | $ | 75,000,000 | ||||
Shareholders’ equity (deficit) |
$ | 18,477 | $ | (1,481,523 | ) | |||
∎ |
Our registration statement/proxy statement filed for our business combination transaction would disclose the possibility that our sponsor, initial shareholders, directors, officers, advisors and their affiliates may purchase public shares from public shareholders outside the redemption process, along with the purpose of such purchases; |
∎ |
if our sponsor, initial shareholders, directors, officers, advisors and their affiliates were to purchase public shares from public shareholders, they would do so at a price no higher than the price offered through our redemption process; |
∎ |
our registration statement/proxy statement filed for our business combination transaction would include a representation that any of our securities purchased by our sponsor, initial shareholders, directors, officers, advisors and their affiliates would not be voted in favor of approving the business combination transaction; |
∎ |
our sponsor, initial shareholders, directors, officers, advisors and their affiliates would not possess any redemption rights with respect to our securities or, if they do acquire and possess redemption rights, they would waive such rights; and |
∎ |
we would disclose in a Form 8-K, before our security holder meeting to approve the business combination transaction, the following material items: |
∎ |
the amount of our securities purchased outside of the redemption offer by our sponsor, initial shareholders, directors, officers, advisors and their affiliates, along with the purchase price; |
∎ |
the purpose of the purchases by our sponsor, initial shareholders, directors, officers, advisors and their affiliates; |
∎ |
the impact, if any, of the purchases by our sponsor, initial shareholders, directors, officers, advisors and their affiliates on the likelihood that the business combination transaction will be approved; |
∎ |
the identities of our security holders who sold to our sponsor, initial shareholders, directors, officers, advisors and their affiliates (if not purchased on the open market) or the nature of our security holders (e.g., 5% security holders) who sold to our sponsor, initial shareholders, directors, officers, advisors and their affiliates; and |
∎ |
the number of our securities for which we have received redemption requests pursuant to our redemption offer. |
∎ |
restrictions on the nature of our investments; |
∎ |
restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial business combination. In addition, we may have imposed upon us burdensome requirements, including: |
∎ |
registration as an investment company; |
∎ |
adoption of a specific form of corporate structure; and |
∎ |
reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations. |
∎ |
may significantly dilute the equity interest of investors in this offering, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one |
∎ |
may subordinate the rights of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded our Class A ordinary shares; |
∎ |
could cause a change in control if a substantial number of Class A ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
∎ |
may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and |
∎ |
may adversely affect prevailing market prices for our Class A ordinary shares. |
∎ |
default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
∎ |
acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
∎ |
our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; |
∎ |
our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; |
∎ |
using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for expenses, capital expenditures, acquisitions and other general corporate purposes; |
∎ |
limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
∎ |
increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
∎ |
limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. |
∎ |
solely dependent upon the performance of a single business, property or asset, or |
∎ |
dependent upon the development or market acceptance of a single or limited number of products, processes or services. |
∎ |
costs and difficulties inherent in managing cross-border business operations; |
∎ |
rules and regulations regarding currency redemption; |
∎ |
complex corporate withholding taxes on individuals; |
∎ |
laws governing the manner in which future business combinations may be effected; |
∎ |
exchange listing and/or delisting requirements; |
∎ |
tariffs and trade barriers; |
∎ |
regulations related to customs and import/export matters; |
∎ |
local or regional economic policies and market conditions; |
∎ |
unexpected changes in regulatory requirements; |
∎ |
challenges in managing and staffing international operations; |
∎ |
longer payment cycles; |
∎ |
tax issues, such as tax law changes and variations in tax laws as compared to the United States; |
∎ |
currency fluctuations and exchange controls; |
∎ |
rates of inflation; |
∎ |
challenges in collecting accounts receivable; |
∎ |
cultural and language differences; |
∎ |
employment regulations; |
∎ |
underdeveloped or unpredictable legal or regulatory systems; |
∎ |
corruption; |
∎ |
protection of intellectual property; |
∎ |
social unrest, crime, strikes, riots and civil disturbances; |
∎ |
regime changes and political upheaval; |
∎ |
terrorist attacks, natural disasters, widespread health emergencies and wars; and |
∎ |
deterioration of political relations with the United States. |
∎ |
a limited availability of market quotations for our securities; |
∎ |
reduced liquidity for our securities; |
∎ |
a determination that our Class A ordinary shares are a “penny stock” which will require brokers trading in our Class A ordinary shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; |
∎ |
a limited amount of news and analyst coverage; and |
∎ |
a decreased ability to issue additional securities or obtain additional financing in the future. |
Public shares |
7,500,000 | |||
Founder shares |
1,875,000 | |||
Private placement shares |
300,000 | |||
Total shares |
9,675,000 | |||
Total funds in trust available for initial business combination (1) |
$ | 72,000,000 | ||
Implied value per share upon business combination (1)(2) |
$ | 7.44 | ||
Public shareholders’ investment per share |
$ | 10.00 | ||
Sponsor’s investment per share (3) |
$ | 1.39 |
(1) |
Does not take into account other potential impacts on our valuation at the time of the business combination, such as the trading price of our public shares, the terms of the business combination transaction (including any equity issued to or retained by, or cash or other consideration paid to, the target’s shareholder or other third parties), the business combination transaction costs (including payment of up to $3,000,000 of deferred underwriting commissions), or the target’s business itself, including its assets, liabilities, management and prospects. For instance, the potential dilution experienced by holders of our ordinary shares may be mitigated if the business combination agreement is structured such that the potential dilutive impact of the founder shares is borne by all shareholders in the pro forma company. |
(2) |
Note that redemptions of our public shares in connection with our initial business combination would further reduce the implied value of our ordinary shares. For instance, in this example, if 50% of the public shares were redeemed in connection with our initial business combination, the implied value per ordinary share would be $3.72. |
(3) |
The sponsor’s total investment in the equity of the company, inclusive of the founder shares and the sponsor’s $3,000,000 investment in the private placement shares, is $3,025,000. |
∎ |
the history and prospects of companies whose principal business is the acquisition of other companies; |
∎ |
prior offerings of those companies; |
∎ |
our prospects for acquiring an operating business at attractive values; |
∎ |
a review of debt to equity ratios in leveraged transactions; |
∎ |
our capital structure; |
∎ |
an assessment of our management and their experience in identifying operating companies; |
∎ |
general conditions of the securities markets at the time of this offering; and |
∎ |
other factors as were deemed relevant. |
∎ |
our being a blank check company with no operating history or revenue; |
∎ |
our ability to select an appropriate target business or businesses; |
∎ |
our ability to complete our initial business combination; |
∎ |
our expectations around the performance of the prospective target business or businesses; |
∎ |
our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
∎ |
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; |
∎ |
the proceeds of the forward purchase shares being available to us; |
∎ |
our potential ability to obtain additional financing to complete our initial business combination; |
∎ |
our pool of prospective target businesses; |
∎ |
our ability to consummate an initial business combination due to the uncertainty resulting from geopolitical events like the conflicts in Ukraine, Iran and Israel, economic impacts such as inflation and rising interest rates and the COVID-19 pandemic; |
∎ |
the adverse impacts of certain events (such as terrorist attacks, natural disasters or a significant outbreak of infectious diseases) on our ability to consummation an initial business combination; |
∎ |
the ability of our officers and directors to generate a number of potential business combination opportunities; |
∎ |
our public securities’ potential liquidity and trading; |
∎ |
the lack of a market for our securities; |
∎ |
the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
∎ |
the trust account not being subject to claims of third parties; or |
∎ |
our financial performance following this offering. |
Gross proceeds |
||||
Gross proceeds from Class A ordinary shares offered to public (1) |
$ | 75,000,000 | ||
Gross proceeds from sale of the private placement shares offered in a private placement to the sponsor |
$ | 3,000,000 | ||
Total gross proceeds |
$ | 78,000,000 | ||
Estimated Offering expenses (2) |
||||
Underwriting commissions (2% of gross proceeds from shares offered to public and excluding the portion of underwriting commissions that are deferred) (3) |
$ | 1,500,000 | ||
Legal fees and expenses |
$ | 300,000 | ||
Printing and engraving expenses |
$ | 35,000 | ||
Accounting fees and expenses |
$ | 60,000 | ||
SEC/FINRA expenses |
$ | 26,000 | ||
Road show expenses |
$ | 15,000 | ||
Nasdaq listing and filing fees |
$ | 75,000 | ||
Miscellaneous |
$ | 239,000 | ||
Total estimated offering expenses (excluding underwriting commissions) |
$ | 750,000 | ||
Reimbursed expenses (5) |
$ | 750,000 | ||
Proceeds after estimated offering expenses (including portion of underwriting commissions that is not deferred) and reimbursement |
$ | 76,500,000 | ||
Held in trust account (4) |
$ | 75,000,000 | ||
% of public offering size |
100% | |||
Not held in trust account |
$ | 1,500,000 |
AMOUNT |
% OF TOTAL |
|||||||
Legal, accounting, due diligence, travel, and other expenses in connection with any business combination |
$ | 400,000 | 26.67 | % | ||||
Legal and accounting fees related to regulatory reporting obligations |
$ | 200,000 | 13.33 | % | ||||
Consulting, travel and miscellaneous expenses incurred during search for initial business combination target |
$ | 100,000 | 6.67 | % | ||||
Nasdaq continued listing fees |
$ | 55,000 | 3.67 | % | ||||
Director & Officer liability insurance premiums |
$ | 400,000 | 26.67 | % | ||||
Working capital to cover miscellaneous expenses and reserves |
$ | 345,000 | 23.00 | % | ||||
Total |
$ | 1,500,000 | 100.0 | % | ||||
(1) |
Includes amounts payable to public shareholders who properly redeem their shares in connection with our successful completion of our initial business combination. |
(2) |
In addition, a portion of the offering expenses have been paid from the proceeds of loans from our sponsor of up to $300,000 as described in this prospectus. As of August 21, 2026, we had borrowed $10,500 under the promissory note with our sponsor. These loans will be repaid upon completion of this offering out of the approximately $750,000 of offering proceeds that has been allocated for the payment of offering expenses (other than underwriting commissions) and not to be held in the trust account. In the event that offering expenses are less than set forth in this table, any such amounts will be used for post-closing working capital expenses. In the event that the offering expenses are more than as set forth in this table, we may fund such excess with funds not held in the trust account. |
(3) |
The underwriter will receive 2% of the gross proceeds of this offering, being $1,500,000, payable at the closing of this offering. In addition, the underwriter has agreed to defer underwriting commissions of 4% of the gross proceeds of this offering. Upon and concurrently with the completion of our initial business combination, $3,000,000, which constitutes the underwriter’s deferred commissions, will be paid to the underwriter from the funds held in the trust account. See “ Underwriting. |
(4) |
These expenses are estimates only. Our actual expenditures for some or all of these items may differ from the estimates set forth herein. For example, we may incur greater legal and accounting expenses than our current estimates in connection with negotiating and structuring our initial business combination based upon the level of complexity of such business combination. In the event we identify a business combination target in a specific industry subject to specific regulations, we may incur additional expenses associated with legal due diligence and the engagement of special legal counsel. In addition, our staffing needs may vary and as a result, we may engage a number of consultants to assist with legal and financial due diligence. We do not anticipate any change in our intended use of proceeds, other than fluctuations among the current categories of allocated expenses, which fluctuations, to the extent they exceed current estimates for any specific category of expenses, would not be available for our expenses. The amount in the table above does not include interest available to us from the trust account. The proceeds held in the trust account will be held in cash, including in demand deposit accounts at a bank, or invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. Assuming an interest rate of 3.75% per year, we estimate the interest earned on the trust account will be approximately $2,812,500 per year; however, we can provide no assurances regarding this amount. |
(5) |
The underwriters have agreed to make a payment to us at the closing of this offering to reimburse certain of our expenses and fees in connection with this offering in an amount equal to 1.0% of the aggregate gross proceeds of the offering. |
| AS OF AUGUST 21, 2026 | ||||||||||||||||||||||||||||||||||
| OFFERING PRICE OF $10.00 PER SHARE |
25% OF MAXIMUM REDEMPTION |
50% OF MAXIMUM REDEMPTION |
75% OF MAXIMUM REDEMPTION |
MAXIMUM REDEMPTION |
||||||||||||||||||||||||||||||
| NTBV | NTBV | DIFFERENCE BETWEEN NTBV AND OFFERING PRICE |
NTBV | DIFFERENCE BETWEEN NTBV AND OFFERING PRICE |
NTBV | DIFFERENCE BETWEEN NTBV AND OFFERING PRICE |
NTBV | DIFFERENCE BETWEEN NTBV AND OFFERING PRICE |
||||||||||||||||||||||||||
| $ | 7.60 | $ | 7.02 | $ | 2.98 | $ | 6.08 | $ | 3.92 | $ | 4.26 | $ | 5.74 | $ | (0.68 | ) | $ | 10.68 | ||||||||||||||||
| NO REDEMPTIONS |
25% OF MAXIMUM REDEMPTIONS |
50% OF MAXIMUM REDEMPTIONS |
75% OF MAXIMUM REDEMPTIONS |
MAXIMUM REDEMPTIONS |
||||||||||||||||
Public offering price |
$ | $ | 10.00 | $ | 10.00 | $ | 10.00 | $ | ||||||||||||
Net tangible book deficit before this offering |
( |
) | (0.03 | ) | (0.03 | ) | (0.03 | ) | ( |
) | ||||||||||
Increase (decrease) attributable to public shareholders |
7.63 | 7.05 | 6.11 | 4.29 | (0.65 | ) | ||||||||||||||
Pro forma net tangible book value (deficit) after this offering and the sale of the private placement shares |
7.02 | 6.08 | 4.26 | ( |
) | |||||||||||||||
Dilution to public shareholders |
2.98 | 3.92 | 5.74 | |||||||||||||||||
Percentage of dilution to public shareholders |
24.0 | % | 29.8 | % | 39.2 | % | 57.4 | % | 106.8 | % | ||||||||||
NO REDEMPTIONS |
25% OF MAXIMUM REDEMPTIONS |
50% OF MAXIMUM REDEMPTIONS |
75% OF MAXIMUM REDEMPTIONS |
MAXIMUM REDEMPTIONS |
||||||||||||||||
Numerator: |
||||||||||||||||||||
Net tangible book deficit before this offering |
$ | ( |
) | $ | (56,151 | ) | $ | (56,151 | ) | $ | (56,151 | ) | $ | ( |
) | |||||
Net proceeds from this offering and the sale of the private placement shares (1) |
76,500,000 | 76,500,000 | 76,500,000 | |||||||||||||||||
Plus: Offering costs accrued for or paid in advance, excluded from tangible book value |
74,628 | 74,628 | 74,628 | |||||||||||||||||
Less: Deferred Underwriting discount (2) |
( |
) | (3,000,000 | ) | (3,000,000 | ) | (3,000,000 | ) | ( |
) | ||||||||||
Less: Amounts paid for redemptions (3) |
(18,750,000 | ) | (37,500,000 | ) | (56,250,000 | ) | ( |
) | ||||||||||||
| 54,768,477 | 36,018,477 | 17,268,477 | ( |
) | ||||||||||||||||
Denominator: |
||||||||||||||||||||
Ordinary shares outstanding prior to this offering |
1,875,000 | 1,875,000 | 1,875,000 | |||||||||||||||||
Ordinary shares offered and sale of private placement shares |
7,500,000 | 7,500,000 | 7,500,000 | |||||||||||||||||
Private placement shares |
300,000 | 300,000 | 300,000 | |||||||||||||||||
Less: Ordinary shares redeemed |
(1,875,000 | ) | (3,750,000 | ) | (5,625,000 | ) | ( |
) | ||||||||||||
| 7,800,000 | 5,925,000 | 4,050,000 | ||||||||||||||||||
(1) |
Expenses applied against gross proceeds include offering expenses of approximately $750,000, underwriting commissions of $1,500,000 and reimbursement by the underwriters of certain of our expenses and fees in connection with this offering of $750,000. See “Use of Proceeds.” |
(2) |
Upon the consummation of our initial business combination, the deferred underwriting commissions will equal 4% of the gross proceeds of t his offering. |
(3) |
If we seek shareholder approval of our initial business combination and we do not conduct redemptions or repurchases in connection with our initial business combination pursuant to the tender offer rules, our sponsor, initial shareholders, directors, executive officers or their affiliates may purchase public shares in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. In the event of any such purchases of our shares prior to the completion of our initial business combination, the number of ordinary shares subject to redemption will be reduced by the amount of any such purchases, increasing the pro forma net tangible book value per share. See “ Proposed Business—Effecting Our Initial Business Combination—Permitted Purchases and Other Transactions with Respect to Our Securities |
SHARES PURCHASED |
TOTAL CONSIDERATION |
AVERAGE PRICE PER SHARE |
||||||||||||||||||
NUMBER |
PERCENTAGE |
AMOUNT |
PERCENTAGE |
|||||||||||||||||
Initial Shareholders (1) |
2,175,000 | 22.48 | % | 3,025,000 | 3.88 | % | $ | 1.39 | ||||||||||||
Public Shareholders |
7,500,000 | 77.52 | % | 75,000,000 | 96.12 | % | $ | 10.00 | ||||||||||||
| 9,675,000 | 100.00 | % | 78,025,000 | 100.00 | % | |||||||||||||||
(1) |
Assumes conversion of Class B ordinary shares into Class A ordinary shares on a one-for-one one-to-one |
AUGUST 21, 2026 |
||||||||
ACTUAL |
AS ADJUSTED |
|||||||
Promissory note—related party (1) |
$ | 10,500 | $ | — | ||||
Deferred underwriting commissions (2) |
— | 3,000,000 | ||||||
Class A ordinary shares subject to possible redemption, $0.0001 par value, 200,000,000 authorized, actual and as adjusted, 0 and 7,500,000 shares issued and outstanding, actual and as adjusted, respectively (3) |
— | 75,000,000 | ||||||
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding, actual and as adjusted |
— | — | ||||||
Class A ordinary shares, $0.0001 par value, 200,000,000 shares authorized; 0 and 300,000 shares issued and outstanding (excluding 7,500,000 shares subject to possible redemption), actual and as adjusted, respectively |
— | 30 | ||||||
Class B ordinary shares, $0.0001 par value, 20,000,000 shares authorized, 2,156,250 and 1,875,000 shares issued and outstanding actual and as adjusted, respectively |
216 | 188 | ||||||
Additional Paid-in capital |
24,784 | — | ||||||
Accumulated deficit |
(6,523 | ) | (1,481,741 | ) | ||||
Total shareholders’ equity (deficit) |
$ | 18,477 | $ | (1,481,523 | ) | |||
Total capitalization |
$ | 28,977 | $ | 76,518,477 | ||||
(1) |
Our sponsor may loan us up to $300,000 under an unsecured promissory note to be used for a portion of the expenses of this offering. As of August 21, 2026, there was $10,500 outstanding under the unsecured promissory note. |
(2) |
$0.40 per share, or $3,000,000 in the aggregate, will be payable to the underwriter for deferred underwriting commissions. The deferred underwriting commissions will become payable to the underwriter from the amounts held in the trust account solely in the event that we complete an initial business combination, subject to the terms of the underwriting agreement. We record deferred underwriting commissions upon the closing of this offering as a reduction of additional paid-in capital. Since the actual additional paid-in capital was reduced by the recording of the accrued deferred underwriting commission, total capitalization, as adjusted, includes the amount of the deferred underwriting commission to reflect total capitalization. |
(3) |
Upon the completion of our initial business combination, we will provide our public shareholders with the opportunity to redeem their public shares for cash at a per share price equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the initial business combination, including interest earned on the funds held in the trust account and not previously released to us to pay taxes, divided by the number of the then-outstanding public shares, subject to any limitations (including, but not limited to, cash requirements) created by the terms of the proposed business combination. |
∎ |
may significantly dilute the equity interest of investors in this offering, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one-to-one |
∎ |
may subordinate the rights of holders of Class A ordinary shares if preference shares are issued with rights senior to those afforded to Class A ordinary shares; |
∎ |
could cause a change in control if a substantial number of Class A ordinary shares are issued, which may affect, among other things, the post-business combination company’s ability to use its net operating loss carry forwards, if any, and could result in the resignation or removal of the post-business combination company’s officers and directors; |
∎ |
may have the effect of delaying or preventing a change of control of the post-business combination company by diluting the share ownership or voting rights of a person seeking to obtain control of the post-business combination company; and |
∎ |
may adversely affect prevailing market prices for our Class A ordinary shares. |
∎ |
default and foreclosure on the assets of the post-business combination company if its operating revenues are insufficient to repay its debt obligations; |
∎ |
acceleration of the post-business combination company’s obligations to repay such indebtedness, even if it makes all principal and interest payments when due, if it breaches certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
∎ |
the post-business combination company’s immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; |
∎ |
post-business combination company’s inability to obtain necessary additional financing if the debt security contains covenants restricting its ability to obtain such financing while the debt security is outstanding; |
∎ |
using a substantial portion of the post-business combination company’s cash flow to pay principal and interest on its debt, which will reduce the funds available for expenses, capital expenditures, acquisitions and other general corporate purposes; |
∎ |
limitations on the post-business combination company’s flexibility in planning for and reacting to changes in its business and in the industry in which it operates; |
∎ |
increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
∎ |
limitations on the post-business combination company’s ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of its strategy and other purposes and other disadvantages compared to its competitors who have less debt. |
∎ |
staffing for financial, accounting and external reporting areas, including segregation of duties; |
∎ |
reconciliation of accounts; |
∎ |
proper recording of expenses and liabilities in the period to which they relate; |
∎ |
evidence of internal review and approval of accounting transactions; |
∎ |
documentation of processes, assumptions and conclusions underlying significant estimates; and |
∎ |
documentation of accounting policies and procedures. |
∎ |
Dedicated team and vehicle for public market and crossover investments: follow-on equity offerings, private investments in public equities (“PIPEs”), and open market transactions. |
∎ |
Track record of investing in private companies: |
∎ |
Experienced company founders: in-house professionals who are dedicated to company creation and have historically formed an average of two to three new companies per year. |
∎ |
Deep biopharmaceutical expertise and network: entrepreneurs-in-residence, 1,000-person divisions of large pharmaceutical companies. This group represents strong expertise across the spectrum of drug development in disciplines including medicinal chemistry, pharmacology and translational biology, drug metabolism and pharmacokinetics, toxicology and clinical development. We believe these advisors provide a level of diligence and operational expertise that is critical for both the FLS investment process as well as post-investment value creation. |
∎ |
Leadership continuity: |
∎ |
Targeted product focus |
∎ |
Investing near value inflection points proof-of-concept post-PoC assets, and successful commercial launch post-approval. Consistent with this approach, FLS has historically focused on companies that it believes have the potential to achieve one of these value inflection points within a short time frame following investment. |
∎ |
Backing biopharma performers |
∎ |
Maintaining capital efficiency |
∎ |
Focused on therapeutics for areas of unmet medical need, including in disease areas where FLS has established depth. |
∎ |
Supported by clinical data, or a well-defined path to clinical data, with a value inflection point expected within approximately three years of the business combination. |
∎ |
Led by a management team with a track record of execution and the capability to operate a publicly listed company. |
∎ |
Funded, after giving effect to the business combination, through at least one significant value inflection point. |
ENTITY |
AMOUNT OF COMPENSATION TO BE RECEIVED OR SECURITIES ISSUED OR TO BE ISSUED |
CONSIDERATION PAID OR TO BE PAID | ||
| Frazier Life Sciences Holdings II LLC and other initial shareholders | 1,875,000 Class B ordinary shares, of which 1,683,749 Class B ordinary shares are held by our sponsor and 191,251 Class B ordinary shares are held by our independent directors and Chief Financial Officer. | $25,000 (approximately $0.013 per share after giving effect to the share forfeiture) | ||
| Frazier Life Sciences Holdings II LLC | 300,000 private placement shares | $3,000,000 ($10.00 per share) | ||
| Frazier Life Sciences Holdings II LLC, an affiliate thereof, or our officers and directors | Repayment in cash or up to $3,000,000 in private placement shares of the post-business combination entity at a price of $10.00 per share at the option of the lender | Loans to finance transaction costs in connection with an intended initial business combination | ||
Frazier Life Sciences Holdings II LLC |
Repayment in cash | Up to $300,000 under an unsecured, non-interest bearing promissory note for offering-related and organizational expenses. This loan is due at the earlier of December 31, 2027 or the closing of this offering and is anticipated to be repaid upon completion of this offering out of the $750,000 of offering proceeds that has been allocated for the payment of offering expenses other than underwriting commissions | ||
| Holders of Class B ordinary shares | Anti-dilution protection upon conversion into Class A ordinary shares at a greater than one-to-one |
Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than one-to-one | ||
| Frazier Life Sciences Holdings II LLC, our officers or directors, or affiliates thereof | Repayment in cash | Any out-of-pocket related to identifying, investigating, negotiating and completing an initial business combination | ||
SUBJECT SECURITIES |
EXPIRATION DATE |
PERSONS SUBJECT TO RESTRICTIONS |
EXCEPTIONS TO TRANSFER RESTRICTIONS | |||
| Founder Shares | The founder shares are not transferable or saleable until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any 30-trading day period commencing at least 180 days after the completion of our initial business combination. |
Initial shareholders | Transfers are permitted (a) to us or to our officers or directors, advisors or consultants, any affiliate or family member of any of our officers or directors, advisors or consultants, any members or partners of our sponsor or their affiliates, and funds and accounts advised by such members or partners, any affiliates of our sponsor, or any employees of such affiliates, (b) in the case of an individual, as a gift to such person’s immediate family or to a trust, the beneficiary of which is a member of such person’s immediate family, an affiliate of such person or to a charitable organization, (c) in the case of an individual, by virtue of laws of descent and distribution upon death of such person, (d) in the case of an individual, pursuant to a qualified domestic relations order, (e) by private sales or transfers made in connection with any forward purchase agreement or similar arrangement or in connection with the consummation of a business combination at prices no greater than the price at which the shares were originally purchased, (f) by virtue of the laws of the Cayman Islands or our Sponsor’s limited liability company agreement upon dissolution of our sponsor, (g) in the event of our | |||
SUBJECT SECURITIES |
EXPIRATION DATE |
PERSONS SUBJECT TO RESTRICTIONS |
EXCEPTIONS TO TRANSFER RESTRICTIONS | |||
| liquidation prior to our consummation of our initial business combination, (h) in the event that, subsequent to our consummation of an initial business combination, we complete a liquidation, merger, share exchange or other similar transaction which results in all of our shareholders having the right to exchange their Class A ordinary shares for cash, securities or other property, (i) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (a) through (h) above, or (j) pursuant to an order of a court or regulatory agency; provided, however, that in the case of clauses (a) through (e) or (i) these permitted transferees must enter into a written agreement agreeing to be bound by these transfer restrictions and the other restrictions contained in the letter agreements. | ||||||
| Private Placement Shares | The private placement shares are not transferable or saleable until 30 days after the completion of our initial business combination. | Frazier Life Sciences Holdings II LLC | Same as above. | |||
∎ |
subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and |
∎ |
cause us to depend on the marketing and sale of a single product or limited number of products or services. |
∎ |
We issue ordinary shares that will be equal to or in excess of 20% of the number of our ordinary shares then outstanding (other than in a public offering); |
∎ |
Any of our directors, officers or substantial shareholders (as defined by Nasdaq rules) has a 5% or greater interest earned on the trust account (or such persons collectively have a 10% or greater interest), directly or indirectly, in the target business or assets to be acquired or otherwise and the present or potential issuance of ordinary shares could result in an increase in outstanding ordinary shares or voting power of 5% or more; or |
∎ |
The issuance or potential issuance of ordinary shares will result in our undergoing a change of control. |
∎ |
our registration statement/proxy statement filed for our business combination transaction would disclose the possibility that our sponsor, initial shareholders, directors, officers, advisors and their affiliates may purchase public shares from public shareholders outside the redemption process, along with the purpose of such purchases; |
∎ |
if our sponsor, initial shareholders, directors, officers, advisors and their affiliates were to purchase public shares from public shareholders, they would do so at a price no higher than the price offered through our redemption process; |
∎ |
our registration statement/proxy statement filed for our business combination transaction would include a representation that any of our securities purchased by our sponsor, initial shareholders, directors, officers, advisors and their affiliates would not be voted in favor of approving the business combination transaction; |
∎ |
our sponsor, initial shareholders, directors, officers, advisors and their affiliates would not possess any redemption rights with respect to our securities or, if they do acquire and possess redemption rights, they would waive such rights; and |
∎ |
we would disclose in a Current Report on Form 8-K, before our security holder meeting to approve the business combination transaction, the following material items: |
∎ |
the amount of our securities purchased outside of the redemption offer by our sponsor, initial shareholders, directors, officers, advisors and their affiliates, along with the purchase price; |
∎ |
the purpose of the purchases by our sponsor, initial shareholders, directors, officers, advisors and their affiliates; |
∎ |
the impact, if any, of the purchases by our sponsor, initial shareholders, directors, officers, advisors and their affiliates on the likelihood that the business combination transaction will be approved; |
∎ |
the identities of our security holders who sold to our sponsor, initial shareholders, directors, officers, advisors and their affiliates (if not purchased on the open market) or the nature of our security holders (e.g., 5% security holders) who sold to our sponsor, initial shareholders, directors, officers, advisors and their affiliates; and |
∎ |
the number of our securities for which we have received redemption requests pursuant to our redemption offer. |
∎ |
conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules, and |
∎ |
file proxy materials with the SEC. |
∎ |
conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and |
∎ |
file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
REDEMPTION IN CONNECTION WITH OUR INITIAL BUSINESS COMBINATION |
OTHER PERMITTED PURCHASES OF PUBLIC SHARES BY OUR AFFILIATES |
REDEMPTIONS IF WE FAIL TO COMPLETE AN INITIAL BUSINESS COMBINATION | ||||
Calculation of redemption price |
Redemptions at the time of our initial business combination may be made pursuant to a tender offer or in connection with a shareholder vote. The redemption price will be the same whether we conduct redemptions pursuant to a tender offer or in connection with a shareholder vote. In either case, our public shareholders may redeem their public shares for cash equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of the initial business combination (which is initially anticipated to be $10.00 per share), including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to any limitations (including but not limited to cash requirements) agreed to in connection with the negotiation of terms of a proposed business combination. | If we seek shareholder approval of our initial business combination, our sponsor, directors, officers, advisors or their affiliates may purchase public shares in privately negotiated transactions or in the open market either prior to or following completion of our initial business combination. There is no limit to the prices that our sponsor, directors, officers, advisors or their affiliates may pay in these transactions. If they engage in such transactions, they will not make any such purchases when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited by Regulation M under the Exchange Act. We do not currently anticipate that such purchases, if any, would constitute a tender offer subject to the tender offer rules under the Exchange Act or a going-private transaction subject to the going-private rules under the Exchange Act; however, if the purchasers determine at the time of any such purchases that the purchases are subject to such rules, the purchasers will comply with such rules |
If we are unable to complete our initial business combination within the completion window, we will redeem all public shares at a per-share price, payable in cash, equal to the aggregate amount, then on deposit in the trust account (which is initially anticipated to be $10.00 per share), including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares. |
REDEMPTION IN CONNECTION WITH OUR INITIAL BUSINESS COMBINATION |
OTHER PERMITTED PURCHASES OF PUBLIC SHARES BY OUR AFFILIATES |
REDEMPTIONS IF WE FAIL TO COMPLETE AN INITIAL BUSINESS COMBINATION | ||||
Impact to remaining shareholders |
The redemptions in connection with our initial business combination will reduce the book value per share for our remaining shareholders, who will bear the burden of the deferred underwriting commissions and underwriting commissions and interest withdrawn in order to pay our taxes (to the extent not paid from amounts accrued as interest on the funds held in the trust account). | If the permitted purchases described above are made, there would be no impact to our remaining shareholders because the purchase price would not be paid by us. | The redemption of our public shares if we fail to complete our initial business combination will reduce the book value per share for the shares held by our initial shareholders, who will be our only remaining shareholders after such redemptions. | |||
TERMS OF OUR OFFERING |
TERMS UNDER A RULE 419 OFFERING | |||
Escrow of offering proceeds |
$75,000,000 of the net proceeds of this offering and the sale of the private placement shares will be deposited into a trust account located in the United States with Continental Stock Transfer & Trust Company acting as trustee. | Approximately $63,450,000 of the offering proceeds, representing the gross proceeds of this offering, would be required to be deposited into either an escrow account with an insured depositary institution or in a separate bank account established by a broker-dealer in which the broker-dealer acts as trustee for persons having the beneficial interests in the account. | ||
Investment of net proceeds |
$75,000,000 of the proceeds held in the trust account will initially be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination. and, may at any time be held as cash or cash items, including in demand deposit accounts at a bank. |
Proceeds could be invested only in specified securities such as a money market fund meeting conditions of the Investment Company Act or in securities that are direct obligations of, or obligations guaranteed as to principal or interest by, the United States. | ||
TERMS OF OUR OFFERING |
TERMS UNDER A RULE 419 OFFERING | |||
Receipt of interest on escrowed funds |
Interest on proceeds from the trust account to be paid to shareholders is reduced by (i) any taxes paid or payable (other than excise or similar taxes) and (ii) in the event of our liquidation for failure to complete our initial business combination within the allotted time, up to $100,000 of net interest that may be released to us should we have no or insufficient working capital to fund the costs and expenses of our dissolution and liquidation. | Interest on funds in escrow account would be held for the sole benefit of investors, unless and only after the funds held in escrow were released to us in connection with our completion of a business combination. | ||
Limitation on fair value or net assets of target business |
We must complete one or more business combinations having an aggregate fair market value of at least 80% of our assets held in the trust account (excluding the deferred underwriting commissions and taxes payable on the income earned on the trust account) at the time of the agreement to enter into the initial business combination. | The fair value or net assets of a target business must represent at least 80% of the maximum offering proceeds. | ||
Trading of securities issued |
The shares are expected to begin trading on or promptly after the date of this prospectus. We will file the Current Report on Form 8-K promptly after the closing of this offering, which closing is anticipated to take place three business days from the date of this prospectus. |
No trading of the shares would be permitted until the completion of a business combination. During this period, the securities would be held in the escrow or trust account. | ||
Election to remain an investor |
We will provide our public shareholders with the opportunity to redeem their public shares for cash at a per share price equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the consummation of our initial business combination, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, in connection with the completion of our initial business combination, subject to the limitations and on | A prospectus containing information pertaining to the business combination required by the SEC would be sent to each investor. Each investor would be given the opportunity to notify the company in writing, within a period of no less than 20 business days and no more than 45 business days from the effective date of a post-effective amendment to the company’s registration statement, to decide if he, she or it elects to remain a shareholder of the company or require the return of his, her or its investment. If the company has not received the notification by the end of the 45th | ||
TERMS OF OUR OFFERING |
TERMS UNDER A RULE 419 OFFERING | |||
| the conditions described herein. We may not be required by law to hold a shareholder vote. If we are not required by law and do not otherwise decide to hold a shareholder vote, we will, pursuant to our amended and restated memorandum and articles of association, conduct the redemptions pursuant to the tender offer rules of the SEC and file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination and the redemption rights as is required under the SEC’s proxy rules. If, however, we hold a shareholder vote, we will, like many blank check companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek shareholder approval, we will complete our initial business combination only if it is approved by an ordinary resolution under Cayman Islands law, which requires the affirmative vote of at least a simple majority of the votes cast by the holders of our ordinary shares which are represented in person or, where proxies are allowed, by proxy and entitled to vote on such matter at a general meeting of the company. However, if our initial business combination is structured as a statutory merger or consolidation with another company under Cayman Islands law, the approval of our initial business combination will require a special resolution passed by the affirmative vote of a majority of at least two-thirds of the votes cast by the holders of our ordinary shares which are represented in person or, where proxies are allowed, by proxy and entitled to vote on such matter at a general meeting of the company of which notice specifying the |
business day, funds and interest or dividends, if any, held in the trust or escrow account are automatically returned to the shareholder. Unless a sufficient number of investors elect to remain investors, all funds on deposit in the escrow account must be returned to all of the investors and none of the securities are issued. |
TERMS OF OUR OFFERING |
TERMS UNDER A RULE 419 OFFERING | |||
| intention to propose the resolution as a special resolution has been duly given. Additionally, each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction or whether they do not vote or abstain from voting on the proposed transaction, or whether they were a public shareholder on the record date for the general meeting held to approve the proposed transaction. If we seek shareholder approval for an extension, holders of our public shares will be offered an opportunity to redeem their shares upon approval of such extension, regardless of whether they abstain, vote in favor of or vote against such extension. | ||||
| If we are unable to complete an initial business combination within the completion window, we will as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation or other distributions, if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and subject to the other requirements of applicable law. |
If an acquisition has not been completed within 18 months after the effective date of the company’s registration statement, funds held in the trust or escrow account are returned to investors. | |||
TERMS OF OUR OFFERING |
TERMS UNDER A RULE 419 OFFERING | |||
Release of funds |
Except for the withdrawal of interest to pay our taxes, if any, none of the funds held in trust will be released from the trust account until the earliest of (i) the completion of our initial business combination, (ii) the redemption of our public shares if we are unable to complete our initial business combination within the completion window, subject to applicable law or (iii) the redemption of our public shares properly submitted in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we have not consummated an initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity. |
The proceeds held in the escrow account are not released until the earlier of the completion of a business combination or the failure to effect a business combination within the allotted time. | ||
Delivering share certificates in connection with the exercise of redemption rights |
We intend to require our public shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street name,” to, at the holder’s option, either deliver their share certificates (if any) to our transfer agent or deliver their shares to our transfer agent electronically using the Depository Trust Company’s DWAC (Deposit/ Withdrawal At Custodian) system, prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy materials, this date may be up to two business days prior to the scheduled vote on the proposal to approve the initial business combination. In addition, if we conduct redemptions in connection with a shareholder vote, we intend to require a public shareholder seeking redemption of its public shares to also submit a written request for redemption to our transfer agent two business days prior to the scheduled vote in which the name of the beneficial owner of such shares is included. | Many blank check companies provide that a shareholder can vote against a proposed business combination and check a box on the proxy card indicating that such shareholder is seeking to exercise its redemption rights. After the business combination is approved, the company would contact such shareholder to arrange for delivery of its share certificates to verify ownership. | ||
TERMS OF OUR OFFERING |
TERMS UNDER A RULE 419 OFFERING | |||
| The proxy materials or tender offer documents, as applicable, that we will furnish to holders of our public shares in connection with our initial business combination will indicate whether we are requiring public shareholders to satisfy such delivery requirements. Accordingly, a public shareholder would have up to two business days prior to the scheduled vote on the initial business combination if we distribute proxy materials, or from the time we send out our tender offer materials until the close of the tender offer period, as applicable, to submit or tender its shares if it wishes to seek to exercise its redemption rights. | ||||
Limitation on redemption rights of shareholders holding more than 15% of the shares sold in this offering if we hold a shareholder vote |
If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our amended and restated memorandum and articles of association provide that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to Excess Shares without our prior consent. However, we would not restrict our shareholders’ ability to vote all of their shares (including Excess Shares) for or against our initial business combination. | Many blank check companies provide no restrictions on the ability of shareholders to redeem shares based on the number of shares held by such shareholders in connection with an initial business combination. | ||
NAME |
AGE |
POSITION | ||||
Albert Cha, M.D., Ph.D. |
54 | Chief Executive Officer and Director | ||||
Fran Adams |
45 | Chief Financial Officer | ||||
Kevin Li, M.D. |
34 | Chief Business Officer | ||||
Ali Jackson, J.D. |
36 | General Counsel | ||||
William C. Fairey, Jr. |
62 | Director | ||||
Benjamin L. Palleiko |
61 | Director, Chairman | ||||
R. Scott Struthers, Ph.D. |
65 | Director | ||||
∎ |
assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent registered public accounting firm’s qualifications and independence, and (4) the performance of our internal audit function and independent registered public accounting firm; |
∎ |
the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm and any other independent registered public accounting firm engaged by us; |
∎ |
pre-approving all audit and non-audit services to be provided by the independent registered public accounting firm or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence; |
∎ |
setting clear hiring policies for employees or former employees of the independent auditors; |
∎ |
setting clear policies for audit partner rotation in compliance with applicable laws and regulations; |
∎ |
obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (1) the independent registered public accounting firm’s internal quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues; |
∎ |
meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including reviewing our specific |
disclosures under “ Management’s Discussion and Analysis of Financial Condition and Results of Operations |
∎ |
reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and |
∎ |
reviewing with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. |
∎ |
reviewing and approving on an annual basis the corporate goals and objectives relevant to our chief executive officer’s compensation, evaluating our chief executive officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our chief executive officer’s based on such evaluation; |
∎ |
reviewing and making recommendations to our board of directors with respect to the compensation, and any incentive compensation and equity-based plans that are subject to board approval of all of our other officers; |
∎ |
reviewing our executive compensation policies and plans; |
∎ |
implementing and administering our incentive compensation equity-based remuneration plans; |
∎ |
assisting management in complying with our proxy statement and annual report disclosure requirements; |
∎ |
approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees; |
∎ |
producing a report on executive compensation to be included in our annual proxy statement; and |
∎ |
reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. |
∎ |
identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on our board of directors; |
∎ |
considering and making recommendations to our board of directors regarding the composition and chairmanship of the committees of our board of directors; |
∎ |
instituting plans or programs for the continuing education of our board of directors and orientation of new directors; |
∎ |
developing and making recommendations to our board of directors regarding corporate governance guidelines and matters; and |
∎ |
overseeing periodic evaluations of the board of directors’ performance, including committees of the board of directors and management. |
| (i) | duty to act in good faith in what the director or officer believes to be in the best interests of the company as a whole; |
| (ii) | duty to exercise authority for the purpose for which it is conferred and a duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose; |
| (iii) | directors should not improperly fetter the exercise of future discretion; |
| (iv) | duty to exercise powers fairly as between different sections of shareholders; |
| (v) | duty not to put themselves in a position in which there is a conflict between their duty to the company and their personal interests; and |
| (vi) | duty to exercise independent judgment. |
INDIVIDUAL |
ENTITY |
ENTITY’S BUSINESS |
AFFILIATION | |||
Albert Cha, M.D., Ph.D. |
FLS Ascendis Pharma A/S |
Investment Firm Biopharmaceuticals | Managing Partner Chairman | |||
Fran Adams |
van den Boom and Associates LLC | Accounting Firm | Partner | |||
| Research Alliance Corp. III | SPAC | Chief Financial Officer | ||||
| Research Alliance Corp. IV | SPAC | Chief Financial Officer | ||||
Kevin Li, M.D. |
FLS Angitia Biopharmaceuticals Limited |
Investment Firm Biopharmaceuticals | Partner Director | |||
Ali Jackson, J.D. |
FLS | Investment Firm | Vice President & Counsel | |||
William C. Fairey, Jr. |
Respira Therapeutics, Inc. Mirum Pharmaceuticals, Inc. Rein Therapeutics, Inc. Ascendis Pharma A/S |
Biotechnology Biopharmaceuticals Biopharmaceuticals Biopharmaceuticals | Chairman Director Director Director | |||
Benjamin L. Palleiko. |
FLS | Investment Firm | Senior Advisor | |||
R. Scott Struthers, Ph.D. |
Radionetics Oncology, Inc. | Biotechnology | Chairman | |||
∎ |
Our officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our officers are not obligated to contribute any specific number of hours per week to our affairs. |
∎ |
Our initial shareholders purchased founder shares prior to the date of this prospectus and our sponsor will purchase private placement shares in a transaction that will close simultaneously with the closing of this offering. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and any public shares they may acquire during or after this offering in connection with the completion of our initial business combination. Additionally, our sponsor, officers and directors have agreed to waive their rights to liquidating distributions from the trust account with respect to their founder shares if we fail to complete our initial business combination within the prescribed time frame, although they will be entitled to liquidating distributions from assets outside the trust account. Furthermore, our sponsor, officers and directors have agreed not to transfer, assign or sell any of their founder shares and any Class A ordinary shares issuable upon conversion thereof until one year after the completion of our initial business combination or earlier if the last sale price of our Class A ordinary shares equals or exceeds $12.00 for any 20 trading days within any 30-trading day period commencing at least 180 days after the completion of our initial business combination. Because affiliates of Fraizer and members of our board of directors will directly or indirectly own our securities following this offering, and accordingly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination and in negotiating or accepting the terms of the transaction because of their financial interest in completing an initial business combination within the completion window. |
∎ |
Our sponsor paid a nominal aggregate purchase price of $25,000 for the founder shares, or approximately $0.013 per share (after giving effect to the share forfeiture). Accordingly, our management team, which owns interest in our sponsor, may be more willing to pursue a business combination with a riskier or less established target business than would be the case if our sponsor had paid the same per share price for the founder shares as our public shareholders paid for their public shares. The low price that our sponsor, executive officers and directors (directly or indirectly) paid for the founder shares creates an incentive whereby our officers and directors could potentially make a substantial profit even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. If we are unable to complete our initial business combination within the completion window, the founder shares may expire worthless, except to the extent they receive liquidating distributions from assets outside the trust account, which could create an incentive for our sponsor, executive officers and directors to complete a transaction even if we select an acquisition target that subsequently declines in value and is unprofitable for public shareholders. |
∎ |
In the event our sponsor or members of our management team provide loans to us to finance transaction costs and/or incur expenses on our behalf in connection with an initial business combination, such persons may have a conflict of interest in determining whether a particular target business is an appropriate |
business with which to effectuate our initial business combination as such loans may not be repaid and/or such expenses may not be reimbursed unless we consummate such business combination. |
∎ |
Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors were to be included by a target business as a condition to any agreement with respect to our initial business combination. |
∎ |
each person known by us to be the beneficial owner of more than 5% of our issued and outstanding ordinary shares; |
∎ |
each of our officers and directors; and |
∎ |
all our officers and directors as a group. |
APPROXIMATE PERCENTAGE OF OUTSTANDING ORDINARY SHARES | ||||||||
NAME AND ADDRESS OF BENEFICIAL OWNER (1) |
NUMBER OF ORDINARY SHARES BENEFICIALLY OWNED (2)(4) |
BEFORE OFFERING |
AFTER OFFERING | |||||
Frazier Life Sciences Holdings II LLC (3)(4) |
1,983,749 | 91.2% | 20.5% | |||||
Albert Cha, M.D., Ph.D. (3)(4) |
1,983,749 | 91.2% | 20.5% | |||||
Fran Adams |
14,063 | * | * | |||||
William C. Fairey, Jr |
30,000 | 1.4% | * | |||||
Benjamin L. Palleiko (5) |
117,188 | 5.4% | 1.2% | |||||
R. Scott Struthers, Ph.D. |
30,000 | 1.4% | * | |||||
All officers and directors as a group (seven individuals) |
2,175,000 | 100% | 22.5% | |||||
| * | Less than one percent. |
(1) |
Unless otherwise noted, the business address of each of the following is 1001 Page Mill Road, Building 4, Suite 200B, Palo Alto, California 94304. |
(2) |
Interests shown consist solely of founder shares, classified as Class B ordinary shares. Such shares will automatically convert into Class A ordinary shares immediately prior to, concurrently with or immediately following the consummation of our initial business combination or at any time prior thereto at the option of the holder on a one-for-one Description of Securities |
(3) |
Frazier Life Sciences Holdings II LLC is the record holder of the shares reported herein. Albert Cha, M.D., Ph.D., our Chief Executive Officer and a director, is the manager of Frazier Life Sciences Holdings II LLC and controls the sponsor, including the exercise of voting and investment discretion over the securities of our company held by the sponsor. See the section titled “ Proposed Business—Our Sponsor |
(4) |
Includes 300,000 private placement shares to be purchased by the sponsor in connection with this offering, as further described in this prospectus. Excludes forward purchase shares issuable pursuant to the forward purchase agreement, as such shares will only be issued concurrently with the closing of our initial business combination. |
(5) |
Includes 30,000 founder shares held of record by GTBAP Limited Partnership, a Massachusetts limited partnership (“GTBAP”). Corrugated Capital LLC is the general partner of GTBAP. Mr. Palleiko serves as the sole manager of Corrugated Capital LLC. |
∎ |
7,500,000 Class A ordinary shares issued as part of this offering; |
∎ |
300,000 Class A ordinary shares issued in the private placement to the sponsor; and |
∎ |
1,875,000 Class B ordinary shares held by our initial shareholders. |
∎ |
the names and addresses of the members, together with a statement of the shares held by each member, which: |
∎ |
distinguishes each share by its number (so long as the share has a number), |
∎ |
confirms the amount paid or agreed to be considered as paid, on the shares of each member, |
∎ |
confirms the number and category of shares held by each member, and |
∎ |
confirms whether each relevant category of shares held by a member carries voting rights under the articles of association and if so, whether such voting rights are conditional; |
∎ |
the date on which the name of any person was entered on the register as a member; and |
∎ |
the date on which any person ceased to be a member. |
∎ |
we are not proposing to act illegally or beyond the scope of our corporate authority and the statutory provisions as to majority vote have been complied with; |
∎ |
the shareholders have been fairly represented at the meeting in question; |
∎ |
the arrangement is such as a businessman would reasonably approve; and |
∎ |
the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act or that would amount to a “fraud on the minority.” |
∎ |
a company is acting, or proposing to act, illegally or beyond the scope of its authority; |
∎ |
the act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been obtained; or |
∎ |
those who control the company are perpetrating a “fraud on the minority.” |
∎ |
an exempted company does not have to file an annual return of its shareholders with the Registrar of Companies; |
∎ |
an exempted company’s register of members is not open to inspection; |
∎ |
an exempted company does not have to hold an annual general meeting; |
∎ |
an exempted company may issue shares with no nominal or par value; |
∎ |
an exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 30 years in the first instance); |
∎ |
an exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands; |
∎ |
an exempted company may register as a limited duration company; and |
∎ |
an exempted company may register as a segregated portfolio company. |
∎ |
If we are unable to complete our initial business combination within the completion window, we will as promptly as reasonably possible but no more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, which redemption will constitute full and complete payment for the public shares and completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation or other distributions, if any), subject to our obligations under Cayman Islands law to provide for claims of creditors and subject to the other requirements of applicable law; |
∎ |
Prior to our initial business combination, we may not issue additional securities that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote on our initial business combination; |
∎ |
Although we do not intend to enter into a business combination with a target business that is affiliated with FLS, our sponsor, founders, officers or directors, we are not prohibited from doing so. In the event we enter into such a transaction, we, or a committee of independent directors, will obtain an opinion from an independent investment banking firm or an independent valuation or accounting firm that the consideration to be paid by us in such a business combination is fair to our company from a financial point of view; |
∎ |
If a shareholder vote on our initial business combination is not required by law and we do not decide to hold a shareholder vote for business or other legal reasons, we will offer to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information about our initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act; |
∎ |
If our shareholders approve an amendment to our amended and restated memorandum and articles of association (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity, we will provide our public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of taxes paid or payable (other than excise or similar taxes)), divided by the number of then issued and outstanding public shares, subject to the limitations and on the conditions described herein; |
∎ |
We will not effectuate our initial business combination solely with another blank check company or a similar company with nominal operations; and |
∎ |
Our amended and restated memorandum and articles of association provide that unless we consent in writing to the selection of an alternative forum, the courts of the Cayman Islands shall have exclusive jurisdiction over any claim or dispute arising out of or in connection with our amended and restated memorandum and articles of association or otherwise related in any way to each shareholder’s shareholding in us, including but not limited to (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of any fiduciary or other duty owed by any of our current or former director, officer or other employee to us or our shareholders, (iii) any action asserting a claim arising pursuant to any provision of the Companies Act or our amended and restated memorandum and articles of association, or (iv) any action asserting a claim against us governed by the internal affairs doctrine (as such concept is recognized under the laws of the United States of America) and that each shareholder irrevocably submits to the exclusive jurisdiction of the courts of the Cayman Islands over all such claims or disputes. Our amended and restated memorandum and articles of association also provide that, without prejudice to any other rights or remedies that we may have, each of our shareholders acknowledges that damages alone would not be an adequate remedy for any breach of the selection of the courts of the Cayman Islands as exclusive forum and that accordingly we shall be entitled, without proof of special damages, to the remedies of injunction, specific performance or other equitable relief for any threatened or actual breach of the selection of the courts of the Cayman Islands as exclusive forum. The forum selection provision in our amended and restated memorandum and articles of association will not apply to actions or suits brought to enforce any liability or duty created by the Securities Act, Exchange Act or any claim for which the federal district courts of the United States of America are, as a matter of the laws of the United States of America, the sole and exclusive forum for determination of such a claim. This choice of forum provision may limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits. The enforceability of similar exclusive forum provisions (including exclusive federal forum provisions for actions, suits or proceedings asserting a cause of action arising under the Securities Act) in other companies’ organizational documents has been challenged in legal proceedings, and there is uncertainty as to whether courts would enforce the exclusive forum provisions in our amended and restated memorandum and articles of association. Additionally, our shareholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. |
| (i) | where this is necessary for the performance of our rights and obligations under any purchase agreements; |
| (ii) | where this is necessary for compliance with a legal and regulatory obligation to which we are subject (such as compliance with anti-money laundering and FATCA/CRS requirements); and/or |
| (iii) | where this is necessary for the purposes of our legitimate interests and such interests are not overridden by your interests, fundamental rights or freedoms. |
∎ |
be informed about the purposes for which your personal data are processed; |
∎ |
access your personal data; |
∎ |
stop direct marketing; |
∎ |
restrict the processing of your personal data; |
∎ |
have incomplete or inaccurate personal data corrected; |
∎ |
ask us to stop processing your personal data; |
∎ |
be informed of a personal data breach (unless the breach is unlikely to be prejudicial to you); |
∎ |
complain to the Data Protection Ombudsman; and |
∎ |
require us to delete your personal data in some limited circumstances. |
∎ |
1% of the total number of Class A ordinary shares then outstanding, which will equal 78,000 shares immediately after this offering; or |
∎ |
the average weekly reported trading volume of the Class A ordinary shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. |
∎ |
the issuer of the securities that was formerly a shell company has ceased to be a shell company; |
∎ |
the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; |
∎ |
the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on Form 8-K; and |
∎ |
at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company. |
| 1. | That no law which is hereafter enacted in the Cayman Islands imposing any tax to be levied on profits, income, gains or appreciations shall apply to the Company or its operations; and |
| 2. | In addition, that no tax to be levied on profits, income, gains or appreciations or which is in the nature of estate duty or inheritance tax shall be payable: |
| 2.1 | on or in respect of the shares, debentures or other obligations of the Company; or |
| 2.2 | by way of the withholding in whole or part, of any relevant payment as defined in the Tax Concessions Act (As Revised). |
∎ |
banks; |
∎ |
certain financial institutions; |
∎ |
regulated investment companies and real estate investment trusts; |
∎ |
insurance companies; |
∎ |
brokers or dealers in securities; |
∎ |
traders in securities that elect to use a mark-to-market |
∎ |
tax-exempt organizations or governmental organizations; |
∎ |
U.S. expatriates and former citizens or long-term residents of the United States; |
∎ |
persons holding Class A ordinary shares as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; |
∎ |
persons that actually or constructively own 5% or more of our stock by vote or value; |
∎ |
“controlled foreign corporations,” “foreign controlled foreign corporations,” “passive foreign investment companies,” and corporations that accumulate earnings to avoid U.S. federal income tax; |
∎ |
S corporations, partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); |
∎ |
persons deemed to sell our Class A ordinary shares under the constructive sale provisions of the Code; |
∎ |
persons who hold or receive our Class A ordinary shares pursuant to the exercise of any employee stock option or otherwise as compensation; |
∎ |
tax-qualified retirement plans; |
∎ |
persons subject to special tax accounting rules as a result of any item of gross income being taken into account in an applicable financial statement; and |
∎ |
U.S. Holders whose functional currency is not the U.S. dollar. |
∎ |
an individual who is a citizen or resident of the United States; |
∎ |
a corporation (or other entity taxable as a corporation) created or organized under the laws of the United States, any state thereof, or the District of Columbia; |
∎ |
an estate, the income of which is subject to U.S. federal income tax regardless of its source; or |
∎ |
a trust that (1) is subject to the primary supervision of a U.S. court and the control of one or more “United States persons” (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. |
UNDERWRITER |
NUMBER OF SHARES |
|||
Jefferies LLC |
||||
Total |
7,500,000 | |||
Per Share (1) |
$ | 0.60 | ||
Total (1) |
$ | 4,500,000 |
(1) |
Includes $0.20 per Public Share, or $1,500,000 in the aggregate, payable upon the closing of the proposed public offering. In addition, the underwriters will be entitled to a deferred fee of $0.40 per share, or $3,000,000 in the aggregate payable to the underwriters for deferred underwriting commissions and will be placed in a trust account located in the United States as described herein. The deferred commissions will be fully earned by the underwriters upon the payment of the purchase price for the shares purchased by the underwriters on the closing of this offering and will be released to the underwriters only on and concurrently with completion of an initial business combination. |
∎ |
the purchaser is entitled under applicable provincial securities laws to purchase the securities without the benefit of a prospectus qualified under those securities laws as it is an “accredited investor” as defined under National Instrument 45-106—Prospectus Exemptions, |
∎ |
the purchaser is a “permitted client” as defined in National Instrument 31-103—Registration Requirements, Exemptions and Ongoing Registrant Obligations, |
∎ |
where required by law, the purchaser is purchasing as principal and not as agent, and |
∎ |
the purchaser has reviewed the text above under Resale Restrictions. |
∎ |
a “sophisticated investor” under section 708(8)(a) or (b) of the Corporations Act; |
∎ |
a “sophisticated investor” under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant’s certificate to the Company which complies with the requirements of section 708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made; |
∎ |
a person associated with the Company under Section 708(12) of the Corporations Act; or |
∎ |
a “professional investor” within the meaning of section 708(11)(a) or (b) of the Corporations Act. |
| (a) | to any legal entity which is a qualified investor as defined under the Prospectus Regulation; |
| (b) | to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or |
| (c) | in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of shares shall require the issuer or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. |
∎ |
a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or |
∎ |
a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section 275 of the SFA except: |
∎ |
to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA; |
∎ |
where no consideration is or will be given for the transfer; |
∎ |
where the transfer is by operation of law; |
∎ |
as specified in Section 276(7) of the SFA; or |
∎ |
as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. |
| (a) | to any legal entity which is a qualified investor as defined in Article 2 of the UK Prospectus Regulation; |
| (b) | to fewer than 150 natural or legal persons (other than qualified investors as defined in Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the underwriter for any such offer; or |
| (c) | in any other circumstances falling within section 86 of the Financial Services and Markets Act 2000, as amended, (the “FSMA”), provided that no such offer of shares shall require the issuer or any underwriter to publish a prospectus pursuant to section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. |
∎ |
it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) received by it in connection with the issue or sale of any shares in circumstances in which Section 21(1) of the FSMA does not apply to the issuer; and |
∎ |
it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to any shares in, from or otherwise involving the United Kingdom. |
FRAZIER LIFE SCIENCES ACQUISITION CORP. II
INDEX TO FINANCIAL STATEMENTS
| PAGE | ||||
| Audited Financial Statements of Frazier Life Sciences Acquisition Corp. II: |
||||
| Report of Independent Registered Public Accounting Firm (PCAOB #199) |
F-2 | |||
| F-3 | ||||
| Statement of Operations for the Period from August 7, 2026 (Inception) through August 21, 2026 |
F-4 | |||
| F-5 | ||||
| Statement of Cash Flows for the Period from August 7, 2026 (Inception) through August 21, 2026 |
F-6 | |||
| F-7 | ||||
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Directors of
Frazier Life Sciences Acquisition Corp. II
Opinion on the Financial Statements
We have audited the accompanying balance sheet of Frazier Life Sciences Acquisition Corp. II (the “Company”) as of August 21, 2026, the related statements of operations, shareholder’s equity and cash flows for the period from August 7, 2026 (inception) through August 21, 2026, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of August 21, 2026, and the results of its operations and its cash flows for the period from August 7, 2026 (inception) through August 21, 2026, in conformity with accounting principles generally accepted in the United States of America.
Explanatory Paragraph—Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 to the financial statements, the Company does not have sufficient cash and working capital to sustain its operations for a reasonable period of time, which is generally considered to be one year from the issuance date of the financial statements. The Company’s ability to execute its business plan is dependent upon its completion of a proposed initial public offering. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans with regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
/s/ CBIZ CPAs P.C.
CBIZ CPAs P.C.
We have served as the Company’s auditor since 2026.
New York, NY
September 11, 2026
F-2
FRAZIER LIFE SCIENCES ACQUISITION CORP. II
BALANCE SHEET
AUGUST 21, 2026
| ASSETS |
||||
| Current assets: |
||||
| Prepaid expenses |
$ | 26,477 | ||
|
|
|
|||
| Total Current Assets |
26,477 | |||
| Deferred offering costs |
74,628 | |||
|
|
|
|||
| Total Assets |
$ | 101,105 | ||
|
|
|
|||
| LIABILITIES AND SHAREHOLDER’S EQUITY |
||||
| Accrued offering costs |
$ | 72,128 | ||
|
|
|
|||
| Total Current Liabilities |
72,128 | |||
| Promissory note—Sponsor |
10,500 | |||
|
|
|
|||
| Total Liabilities |
82,628 | |||
| Commitments and Contingencies (Note 5) |
||||
| SHAREHOLDER’S EQUITY |
||||
| Shareholder’s Equity |
||||
| Preference shares, $0.0001 par value, 1,000,000 shares authorized; none issued and outstanding |
— | |||
| Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; none issued and outstanding |
— | |||
| Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 2,156,250 shares issued and outstanding |
216 | |||
| Additional paid-in-capital |
24,784 | |||
| Accumulated deficit |
(6,523 | ) | ||
|
|
|
|||
| Total Shareholder’s Equity |
18,477 | |||
|
|
|
|||
| TOTAL LIABILITIES AND SHAREHOLDER’S EQUITY |
$ | 101,105 | ||
|
|
|
The accompanying notes are an integral part of these financial statements.
F-3
FRAZIER LIFE SCIENCES ACQUISITION CORP. II
STATEMENT OF OPERATIONS
FOR THE PERIOD FROM AUGUST 7, 2026 (INCEPTION) THROUGH AUGUST 21, 2026
| General, formation and administrative expenses |
$ | 6,523 | ||
|
|
|
|||
| Net loss |
$ | (6,523 | ) | |
|
|
|
|||
| Basic and diluted net loss per ordinary share |
$ | (0.00 | ) | |
|
|
|
|||
| Weighted average ordinary shares outstanding, basic and diluted |
1,437,500 | |||
|
|
|
The accompanying notes are an integral part of these financial statements.
F-4
FRAZIER LIFE SCIENCES ACQUISITION CORP. II
STATEMENT OF CHANGES IN SHAREHOLDER’S EQUITY
FOR THE PERIOD FROM AUGUST 7, 2026 (INCEPTION) THROUGH AUGUST 21, 2026
| CLASS B ORDINARY SHARES | ADDITIONAL PAID-IN CAPITAL |
ACCUMULATED DEFICIT |
TOTAL SHAREHOLDER’S EQUITY |
|||||||||||||||||
| SHARES | AMOUNT | |||||||||||||||||||
| Balance as of August 7, 2026 (Inception) |
— | $ | — | $ | — | $ | — | $ | — | |||||||||||
| Issuance of Class B ordinary shares to Sponsor |
2,156,250 | 216 | 24,784 | — | 25,000 | |||||||||||||||
| Net loss |
— | — | — | (6,523 | ) | (6,523 | ) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Balance as of August 21, 2026 |
2,156,250 | $ | 216 | $ | 24,784 | $ | (6,523 | ) | $ | 18,477 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
The accompanying notes are an integral part of these financial statements.
F-5
FRAZIER LIFE SCIENCES ACQUISITION CORP. II
STATEMENTS OF CASH FLOWS
FOR THE PERIOD FROM AUGUST 7, 2026 (INCEPTION) THROUGH AUGUST 21, 2026
| Cash Flows from Operating Activities: |
||||
| Net loss |
$ | (6,523 | ) | |
| Changes in operating assets |
||||
| Prepaid expenses |
(26,477 | ) | ||
|
|
|
|||
| Net cash used in operating activities |
$ | (33,000 | ) | |
|
|
|
|||
| Cash Flows from Financing Activities |
||||
| Proceeds from issuance of Class B ordinary shares to Sponsor |
$ | 25,000 | ||
| Proceeds from promissory note—sponsor |
10,500 | |||
| Payment of deferred offering costs |
(2,500 | ) | ||
|
|
|
|||
| Net cash provided by financing activities |
$ | 33,000 | ||
|
|
|
|||
| Net Change in Cash |
— | |||
| Cash—beginning of the period |
— | |||
|
|
|
|||
| Cash—end of the period |
$ | — | ||
|
|
|
|||
| Supplemental disclosure of non-cash investing and financing activities: |
||||
| Deferred offering costs included in accrued offering costs |
$ | 72,128 |
The accompanying notes are an integral part of these financial statements.
F-6
FRAZIER LIFE SCIENCES ACQUISITION CORP. II
NOTES TO FINANCIAL STATEMENTS
Note 1—Description of Organization and Business Operations
Frazier Life Sciences Acquisition Corp. II (the “Company”) is a newly organized blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). The Company has not selected any specific Business Combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any Business Combination target with respect to an initial Business Combination with the Company. The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.
As of August 21, 2026, the Company had not commenced any operations. All activity for the period from August 7, 2026 (inception) through August 21, 2026 relates to the Company’s formation and the proposed initial public offering described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Proposed Public Offering (as defined below). The Company has selected December 31 as its fiscal year end.
The Company’s ability to commence operations is contingent upon obtaining adequate financial resources through a proposed public offering (the “Proposed Public Offering”) of 7,500,000 Class A ordinary shares (each, a “Public Share” and collectively, the “Public Shares”) at $10.00 per Public Share, which is discussed in Note 3, the sale of 300,000 Class A ordinary shares (each, a “Private Placement Share” and collectively, the “Private Placement Shares”), at a price of $10.00 per Private Placement Share in a private placement to the Sponsor that will close simultaneously with the Proposed Public Offering.
The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Proposed Public Offering and the sale of Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). Upon the closing of the Proposed Public Offering, management has agreed that an amount equal to at least $10.00 per Public Share sold in the Proposed Public Offering, including certain proceeds from the sale of the Private Placement Shares, will be held in a trust account (“Trust Account”), located in the United States, with Continental Stock Transfer & Trust Company acting as trustee, and will be held in cash or invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below.
The Company will provide the holders (the “Public Shareholders”) of Public Shares, with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the
F-7
Company to pay income taxes). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 5).
Upon the public announcement of the initial Business Combination, if the Company elects to conduct redemptions pursuant to the tender offer rules, the Company and the Sponsor will terminate any plan established in accordance with Rule 10b5-1 to purchase the Class A ordinary shares in the open market, in order to comply with Rule 14e-5 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In the event the Company conducts redemptions pursuant to the tender offer rules, the offer to redeem will remain open for at least 20 business days, in accordance with Rule 14e-1(a) under the Exchange Act, and the Company will not be permitted to complete the initial Business Combination until the expiration of the tender offer period. In addition, the tender offer will be conditioned on public shareholders not tendering more than the number of public shares the Company is permitted to redeem. If public shareholders tender more shares than the Company has offered to purchase, the Company will withdraw the tender offer and not complete such initial Business Combination.
Notwithstanding the foregoing, if the Company seeks shareholder approval of its Business Combination and does not conduct redemptions in connection with its Business Combination pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association will provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its Public Shares with respect to more than an aggregate of 15% of the Public Shares issued in the Proposed Public Offering, without the prior consent of the Company.
The Company’s Sponsor, officers and directors (the “initial shareholders”) have agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to provide holders of its Public Shares the right to have their shares redeemed in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete its Business Combination within 24 months from the closing of the Proposed Public Offering (the “Combination Period”) or (b) with respect to any other provision relating to the rights of Public Shareholders, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to the Company to pay its income taxes, if any, divided by the number of the then-outstanding Public Shares.
If the Company has not completed a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes that were paid by the Company or are payable by the Company, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii) to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
The initial shareholders have agreed to waive their liquidation rights with respect to the Founder Shares and Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Proposed Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriter has agreed to waive its right to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares.
F-8
In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution (including Trust Account assets) will be only $10.00 per share initially held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party (excluding the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company have entered into a written letter of intent, confidentially or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.00 per Public Share due to reductions in the value of the trust assets. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriter of the Proposed Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”).
Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Sponsor has not made reserves for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Sponsor’s only assets are securities of the Company. Therefore, the Sponsor may not be able to satisfy those obligations. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (excluding the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.
Note 2—Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (the “US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).
As of August 21, 2026 the Company had no cash and a working capital deficit of $45,651. The Company expects to incur significant costs in pursuit of its acquisition plans. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-40, “Presentation of Financial Statements—Going Concern,” the Company lacks the financial resources it needs to sustain operations for a reasonable period of time, which is considered to be one year from the date of the issuance of the financial statements. This condition raises substantial doubt about the Company’s ability to continue as a going concern. Management plans to address this uncertainty through the Proposed Offering. There is no assurance that the Company’s plans to raise capital will be successful. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Emerging Growth Company
The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an
F-9
emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.
Deferred Offering Costs
The Company complies with the requirements of the ASC 340-10-S99 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A—“Expenses of Offering.” Deferred offering costs consist principally of professional and registration fees that are related to the Proposed Public Offering. FASB ASC 470-20, “Debt with Conversion and Other Options,” addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate Proposed Public Offering proceeds from the Public Shares using the residual method. Offering costs allocated to the Class A ordinary shares will be charged to temporary equity. Should the Proposed Public Offering prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will be charged to operations.
Net Loss Per Ordinary Share
Net loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. At August 21, 2026, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted loss per ordinary share is the same as basic loss per ordinary share for the period presented.
Income Taxes
The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of August 21, 2026, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.
The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company’s tax provision was zero for the period presented.
F-10
Derivative Financial Instruments
The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging.” For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.
Share-based Compensation
The Company records share-based compensation in accordance with FASB ASC Topic 718, “Compensation-Share Compensation” (“ASC 718”), guidance to account for its share-based compensation. It applies a fair value-based method of accounting for an employee share option or similar equity instrument. The Company recognizes all forms of share-based payments at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest. Share-based payments are valued by multiplying the marketable value per Founder Share (defined in Note 4) by the probability of successful closing of an initial Business Combination. Grants of share-based payment awards issued to non-employees for services rendered have been recorded at the fair value of the share-based payment, which is the more readily determinable value. The grants are amortized on a straight-line basis over the requisite service periods, which is generally the vesting period. If an award is granted, but vesting does not occur, any previously recognized compensation cost is reversed in the period related to the termination of service.
Recent Accounting Pronouncements
The Company’s management does not believe that any recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying financial statements.
Note 3—Proposed Public Offering
Pursuant to the Proposed Public Offering, the Company intends to offer for sale 7,500,000 Public Shares at a price of $10.00 per Public Share.
Note 4—Related Party Transactions
Founder Shares
On August 12, 2026, the Sponsor paid $25,000 to cover certain of the Company’s expenses in exchange for the issuance of 2,156,250 Class B ordinary shares, par value $0.0001 (the “Founder Shares”). In August and September 2026, the Sponsor transferred 195,190 Founder Shares to certain directors and executives for an aggregate purchase price of $2,263. In September 281,250 founder shares were forfeited for no consideration, including 3,939 forfeited by an independent director and executive. After the transfer and forfeiture the Sponsor now holds 1,683,749 Founder Shares and the directors and executives hold 191,251 Founder Shares.
The initial shareholders will agree not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination and (B) subsequent to the initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property.
The Founder Shares issued in August 2026 to the Company’s independent directors and executives were made in exchange for an aggregate purchase price of $1,915. The transfer of the Founder Shares to the holders of such interests are in the scope of ASC 718. Under ASC 718, share-based compensation associated with equity classified awards is measured at fair value upon the assignment date. The total fair value of the 165,190 Founder Shares issued in August 2026 was $354,464 or $2.15 per share. The Company established the initial fair value of the Founder Shares using a calculation prepared by a third party valuation team using the Finnerty Model using the following assumptions (i) volatility of 19.69%, (ii) discount for lack of marketability of 6.70% (iii) expected life of
F-11
2.19 years and (iv) likelihood of Business Combination of 23%. The Founder Shares were assigned subject to a performance condition (i.e., providing services through Business Combination). Share-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of shares that ultimately vest times the assignment date fair value per share (unless subsequently modified) less the amount initially received for the Founder Shares. As of August 21, 2026, the Company determined that the initial Business Combination is not considered probable and therefore no compensation expense has been recognized.
Private Placement Shares
The Sponsor will agree to purchase an aggregate of 300,000 Private Placement Shares at a price of $10.00 per Private Placement Share ($3,000,000 in the aggregate) in a private placement that will occur simultaneously with the closing of the Proposed Public Offering. Such Private Placement Shares are identical to the Class A ordinary shares sold in the Proposed Public Offering. If the Company does not consummate an initial Business Combination within 24 months from the closing of the Proposed Public Offering, any proceeds from the sale of the Private Placement Shares held in the trust account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). Holders of the Private Placement Shares have entered into an agreement, pursuant to which they have agreed to waive their redemption rights with respect to their Founder Shares, Private Placement Shares and Public Shares in connection with (i) the completion of the initial Business Combination and (ii) a shareholder vote to approve an amendment to the amended and restated memorandum and articles of association (A) that would modify the substance or timing of the obligation to provide holders of the Class A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete the initial Business Combination within 24 months from the closing of this offering or (B) with respect to any other provision relating to the rights of holders of the Class A ordinary shares. The Private Placement Shares will not be transferable or salable until 30 days after the completion of the initial Business Combination. Certain proceeds from the Private Placement Shares will be added to the proceeds from the Proposed Public Offering to be held in the Trust Account.
Promissory Note—Sponsor
On August 12, 2026, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Proposed Public Offering pursuant to a promissory note (the “Note”). This loan is non-interest bearing and payable on the earlier of December 31, 2027 or the completion of the Proposed Public Offering. As of August 21, 2026, the Company had borrowed $10,500 against the Note.
Related Party Loans
In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $3.0 million of such Working Capital Loans may be convertible into shares of the post Business Combination entity at a price of $10.00 per share. The shares would be identical to the Private Placement Shares. As of August 21, 2026, the Company had no outstanding borrowings under the Working Capital Loans.
Note 5—Commitments & Contingencies
Registration Rights
The initial shareholders as the holders of the Founder Shares and Private Placement Shares, including from time to time the Private Placement Shares that may be issued upon conversion of Working Capital Loans and any Class A ordinary shares issuable upon conversion of Founder Shares, will be entitled to registration rights pursuant to a registration and shareholder rights agreement to be signed in connection with the consummation of the Proposed Public Offering. The holders of these securities are entitled to make up to three demands, excluding short form
F-12
demands, that the Company register such securities. In addition, the holders have certain “piggyback” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
The underwriter will be entitled to an underwriting discount of $0.20 per share, or $1,500,000 in the aggregate, payable upon the closing of the Proposed Public Offering. In addition, the underwriter will be paid deferred underwriting commissions of $0.40 per share, or $3,000,000 in the aggregate, which will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
Note 6—Shareholder’s Equity
Preference Shares—The Company is authorized to issue 1,000,000 preference shares at a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of August 21, 2026, there were no preference shares issued or outstanding.
Class A Ordinary Shares—The Company is authorized to issue 200,000,000 Class A ordinary shares with a par value of $0.0001 per share. As of August 21, 2026, there were no Class A ordinary shares issued or outstanding.
Class B Ordinary Shares—The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. As of August 21, 2026, there were 2,156,250 Class B ordinary shares outstanding.
Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Holders of Class A ordinary shares and holders of Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the shareholders except as required by law. Unless otherwise specified in the amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are represented in person or by proxy and are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least two-thirds of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company, and pursuant to the amended and restated memorandum and articles of association; such actions include amending the amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares entitled to vote and voted for the appointment of directors can elect all of the directors. The shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. Prior to the initial Business Combination, only holders of the Founder Shares will have the right to vote on the appointment of directors. Holders of the Public Shares will not be entitled to vote on the appointment of directors during such time. Further, prior to the closing of the Business Combination, only holders of the Class B ordinary shares will be entitled to vote on transferring the Company by way of continuation in a jurisdiction outside the Cayman Islands (including any special resolution required to amend the constitutional documents of the Company or to adopt new constitutional documents of the company, in each case, as a result of the company approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands) and, as a result, the initial shareholders will be able to approve any such proposal without the vote of any other shareholder. The provisions of the amended and restated memorandum and articles of association governing the appointment of directors prior to the Business Combination and the Company’s continuation in a jurisdiction outside the Cayman Islands prior to the initial Business Combination may only be amended by a special resolution passed by holders representing at least two-thirds of the Company’s outstanding Class B ordinary shares.
Subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein, the Founder Shares, which are designated as Class B ordinary shares, will be convertible at the option of the holder on a one-for-one basis or will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the initial Business Combination at a ratio such that the number of Class A ordinary shares issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 15% of the sum of (i) the total number of ordinary shares issued and
F-13
outstanding (excluding the Private Placement Shares and including any Class B ordinary shares assuming they are converted into Class A ordinary shares) upon completion of this offering, plus (ii) the sum of the total number of Class A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class A ordinary shares or equity-linked securities exercisable for or convertible into Class A ordinary shares issued, deemed issued, or to be issued, to any seller in the Business Combination and any Private Placement Shares issued to the Sponsor, members of the management team or any of their affiliates upon conversion of working capital loans. In no event will the Class B ordinary shares convert into Class A ordinary shares at a rate of less than one to one.
Note 7—Segment Information
ASC Topic 280, “Segment Reporting,” establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker (“CODM”), or group, in deciding how to allocate resources and assess performance.
The Company’s chief operating decision maker has been identified as the Company’s chief executive officer, who review the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one reportable segment.
The CODM assesses performance for the single segment and decides how to allocate resources based on net income or loss that also is reported on the statement of operations as net income or loss. The measure of segment assets is reported on the balance sheet as total assets. When evaluating the Company’s performance and making key decisions regarding resource allocation the CODM reviews certain metrics, which include the following:
| PERIOD FROM AUGUST 7, 2026 (INCEPTION) TO AUGUST 21, 2026 |
||||
| General, formation and administrative expenses |
$ | 6,523 | ||
Formation, general and administrative expenses are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a Proposed Offering and eventually a Business Combination within the business combination period. The CODM also reviews formation, general and administrative expenses to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. Formation, general and administrative expenses, as reported on the statement of operations, are the significant segment expenses provided to the CODM on a regular basis.
Note 8—Subsequent Events
The Company has evaluated subsequent events and transactions that occurred after the balance sheet date through the date that the financial statements are issued. Based upon this review, no subsequent events occurred that would require recognition or disclosure in the financial statements except as disclosed in Note 4.
F-14
7,500,000 Class A Ordinary Shares
Frazier Life Sciences Acquisition Corp. II
PRELIMINARY PROSPECTUS
, 2026
Sole Book-Running Manager:
Jefferies
Until , 2026 (25 days after the date of this prospectus), all dealers that buy, sell or trade our securities whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
| Item 13. | Other Expenses of Issuance and Distribution. |
The estimated expenses payable by us in connection with the offering described in this registration statement (other than the underwriting discount and commissions) will be as follows:
| Legal fees and expenses |
$ | 300,000 | ||
| Accounting fees and expenses |
60,000 | |||
| SEC/FINRA expenses |
26,000 | |||
| Road show expenses |
15,000 | |||
| Exchange listing fee |
75,000 | |||
| Printing and engraving expenses |
35,000 | |||
| Miscellaneous |
239,000 | |||
|
|
|
|||
| Total |
$ | 750,000 | ||
|
|
|
| Item 14. | Indemnification of Directors and Officers. |
Cayman Islands law does not limit the extent to which a company’s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, civil fraud or the consequences of committing a crime. Our amended and restated memorandum and articles of association will provide for indemnification of our officers and directors to the maximum extent permitted by law, including for any liability incurred in their capacities as such, except through their own willful default, willful neglect, civil fraud or the consequences of committing a crime. We will enter into agreements with our directors and officers to provide contractual indemnification in addition to the indemnification provided for in our amended and restated memorandum and articles of association. We expect to purchase a policy of directors’ and officers’ liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.
Our officers and directors have agreed to waive any right, title, interest or claim of any kind in or to any monies in the trust account, and have agreed to waive any right, title, interest or claim of any kind they may have in the future as a result of, or arising out of, any services provided to us and will not seek recourse against the trust account for any reason whatsoever (except to the extent they are entitled to funds from the trust account due to their ownership of public shares). Accordingly, any indemnification provided will only be able to be satisfied by us if (i) we have sufficient funds outside of the trust account or (ii) we consummate an initial business combination.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
| Item 15. | Recent Sales of Unregistered Securities. |
On August 12, 2026, Frazier Life Sciences Holdings II LLC, our sponsor, paid $25,000, or approximately $0.013 per share, to cover certain of our offering and formation costs in exchange for 1,875,000 founder shares (after giving effect to the share forfeiture in September 2026). In August and September 2026, our sponsor transferred an aggregate of 191,251 founder shares to our independent directors and our Chief Financial Officer, Fran Adams. Such securities were issued in connection with our organization pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act. The number of founder shares outstanding was determined based on the expectation that the total size of this offering would be a maximum of 7,500,000, and therefore that such founder shares would represent 20% of the outstanding shares after this offering (excluding the private placement
II-1
shares). If we increase or decrease the size of this offering, we will effect a share capitalization or share repurchase or redemption or other appropriate mechanism, as applicable, with respect to our Class B ordinary shares immediately prior to the consummation of the offering in such amount as to maintain the ownership of founder shares by our initial shareholders at 20% of our issued and outstanding ordinary shares upon the consummation of this offering (excluding the private placement shares). After taking into account the private placement shares to be issued to the sponsor, our initial shareholders will own an aggregate of 2,175,000 ordinary shares, or 22.5% of our issued and outstanding ordinary shares immediately following the completion of this offering. Our sponsor has committed, pursuant to a written agreement, to purchase an aggregate of 300,000 private placement shares, at a price of $10.00 per private placement share ($3,000,000 in the aggregate), in a private placement that will close simultaneously with the closing of this offering. This issuance will be made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act.
No underwriting discounts or commissions were paid with respect to such sales.
| Item 16. | Exhibits and Financial Statement Schedules. |
Exhibit Index
II-2
| EXHIBIT NO. |
DESCRIPTION | |
| 99.1 | Form of Audit Committee Charter. | |
| 99.2 | Form of Compensation Committee Charter. | |
| 99.3 | Form of Nominating and Corporate Governance Committee Charter. | |
| 99.4 | Form of Compensation Recovery Policy. | |
| 101 | Inline Interactive Data File – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document. | |
| 107 | Filing Fee Table. | |
| Item 17. | Undertakings. |
| (a) | The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. |
| (b) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. |
The undersigned registrant hereby undertakes that:
| (1) | For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. |
| (2) | For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| (3) | For the purpose of determining liability under the Securities Act of 1933 of any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. |
| (4) | For the purpose of determining liability of a registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of an undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: |
II-3
| (a) | any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; |
| (b) | any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by an undersigned registrant; |
| (c) | the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and |
| (d) | any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto in the State of California, on the 23rd day of September, 2026.
| Frazier Life Sciences Acquisition Corp. II | ||
| By: | /s/ Albert Cha | |
| Albert Cha, M.D., Ph.D. | ||
| Chief Executive Officer and Director | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Albert Cha, M.D., Ph.D. and Fran Adams his true and lawful attorney-in-fact, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities to sign any and all amendments including post-effective amendments to this registration statement and any and all registration statements filed pursuant to Rule 462 under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
| NAME |
POSITION |
DATE | ||
| /s/ Albert Cha Albert Cha, M.D., Ph.D. |
Chief Executive Officer and Director (Principal Executive Officer) |
September 23, 2026 | ||
| /s/ Fran Adams Fran Adams |
Chief Financial Officer (Principal Financial and Accounting Officer) |
September 23, 2026 | ||
| /s/ William C. Fairey William C. Fairey |
Director |
September 23, 2026 | ||
| /s/ Benjamin L. Palleiko Benjamin L. Palleiko |
Director |
September 23, 2026 | ||
| /s/ R. Scott Struthers R. Scott Struthers, Ph.D. |
Director |
September 23, 2026 | ||
II-5
AUTHORIZED REPRESENTATIVE
Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, the undersigned has signed this registration statement, solely in its capacity as the duly authorized representative of Frazier Life Sciences Acquisition Corp. II, in the City of Palo Alto in the State of California, on the 23rd day of September, 2026.
| By: | /s/ Albert Cha | |
| Albert Cha, M.D., Ph.D. | ||
| Chief Executive Officer | ||
II-6